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Abstract 
 
Observation of chronic hepatitis E virus (HEV) in immunosuppressed patients, and 
unexplained high hepatitis E virus (HEV) prevalence in the human population raises 
public health concern. The aim of this thesis is to molecular characterize and 
investigate the prevalence of HEV in Swedish wild life and their association with HEV 
transmission to humans. A novel virus was detected in a sample from a Swedish moose 
(Alces alces). The genome was highly divergent with sequence identity of 30-60% to 
other HEVs. Genome sequence and phylogenetic analysis showed closest relationship 
with HEV genotypes1-7 (gt1-7). In addition, three open reading frames (ORFs) was 
also detected, and all these observed properties suggested the virus as a member of the 
Hepeviridae family. Markers for ongoing (HEV RNA) and/or past HEV infection (anti-
HEV) was demonstrated in 67 (29%) of 231 Swedish moose samples collected from 
various Swedish provinces. Thus, moose are frequently infected with HEV. Its closest 
similarity with the HEV gt1-7 group, which includes strains that also infects humans, 
may indicate a potential for zoonotic transmission of this HEV. A survey detected HEV 
markers in the wild life, which included samples from wild boars (Sus scrofa) and 
different deer species, fallow deer (Darna darna), red deer (Cervus elaphus), roe deer 
(Capreolus capreolus) and moose (Alces alces). These markers were ongoing and/or 
past infections, and were found in 53 (22%) out of 245 animal samples. The viral 
nucleic acid sequences strains were sequenced and compared with autochthonous 
Swedish human HEV cases, of whom three were found infected with strains similar to 
wild boar strains. These results indicate that Swedish wild animals are often infected 
with HEV and may be an important source of HEV transmission to humans who come 
into contact with wild animals or eat game meat. The introduction of a single amplicon 
PCR of near complete HEV genomes enabled the identification of possible virulence 
marker, and the detection of possible recombination events between Swedish swine and 
wild boar, and that there may have been zoonotic transmission of HEV strains between 
Spain and France.  
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1 Introduction  
1.1 Hepatitis E Virus (HEV): One virus with many faces in 
different places  
The disease previously associated with enterically transmitted none-A to D 
hepatitis, now known as hepatitis E, is an infectious viral disease caused by the 
agent hepatitis E virus (HEV). The disease is one of the most common cause of 
acute viral hepatitis globally. According to WHO, 20 million people are or 
have been infected with HEV. HEV is a RNA virus with a positive single 
stranded genome. It has caused several human epidemics in India (Chobe et al., 
1997), Pakistan (Rab et al., 1997), China (Zhuang et al., 1991), Africa (Kim et 
al., 2014) and Mexico (Huang et al., 1992). HEV was first recognized as a new 
pathogen during the Kashmir water-borne epidemic in 1978, at that time called 
non-A non-B hepatitis (Khuroo, 1980), but HEV has also retrospectively been 
traced back as the cause to a large outbreak in New Dehli, India in 1957 
(Viswanathan, 1957). In 1981, a similar hepatitis epidemic occurred in a Soviet 
military camp located in Afghanistan and the infectious agent HEV was 
isolated for the first time. The discoverer, Dr. Balayan developed acute 
hepatitis following ingestion of a water phase stool suspensions from the 1981 
water-borne epidemic and he sampled his stool and blood during his illness. 
These samples were used for further characterization of the virus (Balayan et 
al., 1983). It took almost ten years for the HEV genome to be sequenced after 
the isolation of HEV cDNA from a HEV infected Cynomolgus monkey bile 
(Reyes et al., 1990).       
The clinical properties of acute HEV hepatitis are indistinguishable from 
hepatitis caused by the hepatitis A virus (HAV). The disease course is mostly 
asymptomatic or with mild symptoms, but can also cause severe hepatitis. In 
infected pregnant women the mortality rate is up to 25% (Kamar et al., 2012a; 
Aggarwal, 2011). HEV is important from the public health perspective in 
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developing countries (the Middle East, southeast and central Asia, Africa and 
the American continent), where it frequently cause large epidemics. HEV is 
fecal-orally transmitted, and the transmission is favoured by crowded settings 
with poor hygiene and water sanitation. The spread of the virus is usually 
through consumption of contaminated water or food (Okamoto, 2007). In 
developed countries HEV infection have long been considered as a poor 
hygiene and travel related illness. The situation was not investigated until 
several studies triggered questions why the general population in many 
industrialised countries like USA, Japan, Canada and several European 
countries (including Sweden) had high prevalence of antibodies against HEV 
(anti-HEV), ranging 5-53% in some regions (Kamar et al., 2012a; Mansuy et 
al., 2011; Guo et al., 2010; Olsen et al., 2006). This high prevalence indicates 
widespread asymptomatic HEV infections. The increased numbers of 
autochthonous (locally acquired) sporadic HEV cases with no history of 
travelling to HEV endemic countries raised the question if HEV would have 
other sources than water as viral reservoirs to infect humans (Kamar et al., 
2012a).  
Since the early 1990s, serological evidence of past HEV infections from 
several animal species and in some cases virus detection suggested that animals 
could be infected with HEV-like viruses. The breakthrough came in 1997, 
when a swine HEV strain was identified in the USA for the first time and 
named swine hepatitis E virus (swHEV) (Meng et al., 1997). This new HEV 
variant was also genetically correlated to two human HEV strains isolated in 
the USA from individuals with no history of travelling to endemic HEV 
affected areas (Meng et al., 1997). Since then, it has been found that domestic 
swine and wild boars across the globe are frequently infected by HEV, 
suggesting porcine as the main reservoir for HEV infections (Meng, 2010; 
Widén et al., 2010; Meng et al., 1997). The HEV transmission pathway is 
often unknown in the industrial part of the world with good sanitary conditions. 
However, there are well documented zoonotic reports by ingestion of HEV 
contaminated porcine products (swine/wild boar) or from consumption of deer.  
Apart from the previously mentioned HEV hosts, additional animal species 
can be infected with HEV e.g. rabbit, mongoose and camels. The HEV variants 
infecting these hosts are classified into genotypes 1-7 (gt1-7) and all are 
members of the recently suggested species Orthohepevirus A of the 
Orthohepevirus genus (Smith et al., 2014). Currently, only gt1-4 have been 
associated with human infections, and gt1-2 exclusively have human as host. 
These genotypes are associated with large outbreaks in developing countries 
often due to poor sanitary conditions. Swine and wild boar are possible viral 
reservoirs for gt3 and gt4 which both have zoonotic properties (Meng, 2013; 
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Meng, 2010). The discovery of new HEV variants found in a wide range of 
animal species has led to important HEV classification changes (Smith et al., 
2014), that are needed for this, seemingly, ever expanding virus family. Other 
issues include the poor knowledge of its replication and infection pathways, 
mainly because the HEV research progress has been hampered by the lack of 
efficient cell culture and small animal models (Kenney & Meng, 2015). There 
are improved models with potential, but they still suffer from complicated and 
expensive setups and are unsuitable for routine labs. A wide range of 
extrahepatic manifestations and increased incidences of chronic HEV 
infections in immunosuppressed patients also raises concern (Kamar et al., 
2012a). The discovery of HEV in animals, including moose, have broadened 
the known host range and diversity of HEV, and raised public health concerns 
for zoonosis and food safety. High HEV seroprevalence in the human 
population indicate that unidentified sources HEV transmission may exist and 
it is of importance to find these transmission routes. Thus, HEV may exist in 
our “backyard”, but this awareness can be used for minimising the zoonotic 
transmission and indicate better preventive measures.  
1.2 Etiology- Biology of hepatitis E virus (HEV)  
1.2.1 Morphology and genomic organization  
HEV was first sequenced in 1990 (Reyes et al., 1990). Its genome consists of a 
single stranded positive sense RNA, which varies in size from 6.6-7.6kb 
depending on the virus strain described (Thiry et al., 2015). The HEV genome 
is contained in a small, non-enveloped icosahedral symmetric virus capsid of 
about 27-34 nm diameter. HEV was first assigned into the Picornaviridae and 
later the Caliciviridae family, based on the first findings of its morphology and 
other physiochemical properties. Later it was clear that the genomic 
organization was different from Caliciviridae and other existing virus families. 
HEV was therefore classified into its own genus, Hepevirus of the novel 
family, Hepeviridae by the International Committee on Taxonomy of Viruses 
(ICTV). However, with the recent discoveries of several divergent animal 
HEVs, including the HEV found in moose (study I-II) have indicated the need 
for a revised HEV classification. A consensus HEV classification was recently 
presented (Smith et al., 2014) and will most likely represent the update for the 
classification of HEV. This update suggest two genera: Orthohepevirus with 
four species (A-D) and Piscihepevirus with a single species Piscihepevirus A, 
and there seven genotypes (gt1-7) within the Orthohepevirus A species (see 
chapter 1.2.3 for more information). At least strains belonging to gt1-4 appear 
to share the same serotype, i.e. infection with one genotype infers immunity 
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against the other (Emerson & Purcell, 2003). The genome has the features of 
eukaryotic mRNA (Figure 1), and comprises of a 7-methylguanine cap at its 5′ 
end followed by three partial overlapping open reading frames 1-3 (ORF1, 
ORF2 and ORF3) and ends with a poly(A) stretch at the 3′ end (Tam et al., 
1991). Although ORF2-3 are encoded in the main HEV genome, its protein 
expression has been demonstrated to occur through a smaller viral RNA 
species of 2.2kb subgenomic RNA (Graff et al., 2006). In addition, the viral 
genome also has short 5´- and 3´untranslated regions (UTRs), and a region 
covering from the 3´end of ORF1 to the start of ORF2/3, which is homologous 
to a junction region (JR) found in alphaviruses (Purdy et al., 1993). These 
elements are likely to form into complex secondary structures containing 
conserved stem-loops and hairpin structures with properties important for HEV 
RNA replication, translation and packaging (Ahmad et al., 2011; Reyes et al., 
1993). The appearance of the viral genome as mRNA facilitate viral protein 
translation through the caped 5’-end, disguising the viral genome from the 
immune response (Ahmad et al., 2011). Studies have confirmed the ORF1-3 
expression by detecting antibodies against these proteins in HEV infected 
humans and experimental animals (Khudyakov Yu et al., 1994). However, the 
expression kinetics of these proteins during the viral life cycle are still not fully 
understood.  
An investigation showed a 76nt region (at nucleotide position 130 to 206) 
within the 5’ UTR that could bind with the N-terminal end of ORF2, 
suggesting it to function as a RNA encapsidation signal (Surjit et al., 2004). 
The end of ORF2 and the 3’UTR are believed to form secondary structures and 
have been demonstrated to bind to a cloned recombinant HEV RNA dependent 
RNA polymerase (RdRp), indicating an important role in the HEV replication 
process (Agrawal et al., 2001; Emerson et al., 2001). Viral proteins have 
beside their essential function to replicate and encapsidate the viral genome, 
also displayed additional functions for host cellular protein interaction. All 
ORF1-3 have shown such interactions, see following section for more 
information. 
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Figure 1. Illustration of the ~7.2kb HEV genome consisting of a cap at its 5’ end and terminates 
with a poly(A) tail at its 3’ end. Nucleotide (nt) and amino acid (aa) position based on gt1-
SAR55. There are also short sections of untranslated regions (UTRs) at 5’ and 3’ ends that folds 
into stem-loop structures (indicated with blue and green colour). These UTRs are involved in 
virus replication, translation and packaging. Three open reading frames 1-3 (ORF1-3) are shown. 
ORF1 encodes a none-structural polyprotein (with the following domains: MeT; 
Methyltransferase; Y: Y-domain; PCP: papain-like cysteine protease; P: poly proline region; X: 
X- or Macro-domain Hel; Helicase RdRp: RNA dependent RNA polymerase) and ends within a 
junction region (JR); Both ORF2-3 proteins are translated from a caped bistronic subgenomic 
RNA that is produced from viral replication starting in the JR. The ORF2 encodes the viral capsid 
with the following regions: ER-signal (purple) and viral RNA binding region (brown), S-, M-, P-
domain. The accessory protein ORF3 contains the following domains (D1, D2, P1 and P2). All 
predicted domains and their possible boundaries positiions are illustrated with numbers. The three 
yellow dots represents glycolysation sites in ORF2 (amino acid position 137, 310 and 562), while 
the red dot is the phosphorylation site in ORF3 at amino acid position 71.  
The ORF1 polyprotein 
The ORF1 (~5.0kb) occupies more than a third of the HEV genome and 
encodes the non-structural poly-protein (pORF1) of about 1693-1704 amino 
acids (aa), (Figure 1). This poly-protein is involved in the replication of the 
viral genome and processing of viral proteins (Ahmad et al., 2011). The ORF1 
consists of six functional domains including a methyltransferase (MeT), 
followed by the Y-domain, a papain-like cysteine protease (PCP), a 
hypervariable region (HVR) with a prolin rich region (PPR),  macro domain 
(X-domain), a RNA helicase and a RNA dependent RNA polymerase (RdRp) 
at the 3’-ORF1 terminal end (Koonin et al., 1992). The predicted MeT 
representing residues 56-240 (Koonin et al., 1992), is suspected for the 5’ 
terminal end capping activities, since both the HEV genomic and subgenomic 
RNAs (encoding ORF2 and ORF3) are capped (Huang et al., 2005; Chen & 
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Meng, 2004; Kabrane-Lazizi et al., 1999b). A cDNA corresponding to amino 
acids 1-979 was expressed in a baculivirus system showing that both 
metyltransferase and guanyltransferase activities were detected (Magden et al., 
2001).  
The subsequent downstream Y domain still remains elusive with unknown 
assigned function. The putative PCP domain between 1300-1779nt/433-592aa 
of ORF1 has long been suspected to have a role in the ORF1 processing 
(Koonin et al., 1992). But its presence and polyprotein processing properties 
still remain controversial and more work has to be performed to clarify if it 
exist and how it function.  
Further downstream is the hypervariable region (HVR), which includes the 
proline rich region (PPR) corresponding to 2137-2337nt/712-778aa. The PPR 
is suggested as an intrinsically disordered region (IDR), rich in polar and 
charged amino acids and may act as a flexible hinge (Purdy, 2012). The 
mutations within the PPR have shown preference for cytosine in the first and 
second codon positions leading to increased frequency of proline residues. The 
PPR of gt1 shows more conservation and less substitution rates compared with 
the zoonotic gt3-4, which may reflect wider host range flexibility of these latter 
genotypes (Purdy et al., 2012). Several studies, including study III reported that 
gt3 can acquire fragment inserted into the PPR regions, but how these 
insertions occur is still unknown. These fragment insertions have frequently 
been observed in strains from immunosuppressed patients with chronic HEV 
infection. Recombinants appears also to have an improved replication capacity 
when tested on cell lines as model (see chapter 1.7.3 from more information). 
It has been shown that the inserted sequences could come from the host cell 
genome or from the virus genome itself, and it is proposed to open new 
protein-protein interactions with new potential regulation sites (Lhomme et al., 
2014a; Purdy, 2012).  
The X- or macro-domain, is the downstream flanking region at position 
2356-2829nt/785-960aa (Neuvonen & Ahola, 2009; Egloff et al., 2006). Macro 
domains can be found in a large range of proteins of bacteria, archaea and 
eukaryotes, and contribute to ADP-ribose metabolism and posttranslational 
modifications (Han et al., 2011). It is suggested that the viral macro domain 
may function as poly (ADP-ribose)-binding unit and is also attracting cellular 
factors for participation in viral RNA replication and/or transcription (Egloff et 
al., 2006). The increased sequence diversity of the PPR and X domain at the 
acute phase of an HEV infection was suggested to be associated with 
persistence of the virus in immunosuppressed solid organ patients (Lhomme et 
al., 2014b).  
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The next following domain (2881-3615nt/960-1204aa) of the HEV ORF1 
region is encoding the helicase, which is essential for the viral replication. The 
putative HEV helicase contains seven motifs that participates in the binding 
and hydrolysis of nucleotides triphosphates (NTPs), and binding of nucleic 
acids (DNA/RNA), (Koonin et al., 1992).  
The RdRp is found in the subsequent flanking region (3546-5106nt/1207-
1693aa). This essential enzyme is found in all RNA viruses. Its function is to 
replicate the genomic RNA. Which most likely occurs through an anti-genomic 
RNA intermediate, in the case of HEV, through a minus sense RNA genome 
intermediate. As in the RdRp of other RNA positive-stranded RNA viruses, 
eight motifs can be found in the HEV RdRp, including GDD amino acid 
sequences that binds Mg2+ required for replicase activity (Koonin et al., 1992). 
The RdRp activity has been demonstrated in HEV replicon systems (Graff et 
al., 2005; Agrawal et al., 2001). 
It is still unclear whether the pORF1is processed into separate components 
or remain unprocessed as a large poly-protein. Studies observing ORF1 
processing into smaller units have been reported (Parvez, 2013; Karpe & Lole, 
2011; Sehgal et al., 2006; Ropp et al., 2000), however contradicting studies 
showing the opposite have also been reported (Perttila et al., 2013; Suppiah et 
al., 2011; Ansari et al., 2000).   
Junction region   
The conserved junction region (JR) including ORF1 stop codon and the start 
codons of the overlapping reading frames ORF2 and ORF3, is predicted to 
encode secondary stem-loop RNA structures (Cao et al., 2010; Huang et al., 
2007). The authentic start codon (AUG) positions of ORF2-3 in JR has been 
investigated in different studies: The first study of liver tissue of macaques 
experimentally infected with HEV, detected three RNA species of 7.2kb, 3.7kb 
and 2kb designated as the genomic and two subgenomic RNA (Tam et al., 
1991). This model suggested that the ORF1 stop codon at position 5105 (gt1 
SAR-55 Strain) overlapped with the ORF3 codon at position 5104. The ORF2 
was suggested to be translated from the 3.7kb subgenomic RNA, while the 
ORF3 was translated with the 2kb subgenomic RNA. However, the 3.7kb 
subgenomic RNA could not be confirmed in other studies. Another challenging 
model from stable Huh-7 cell lines created with HEV RNA replicons 
expressing the neomycin resistance gene from ORF2 and ORF3, showed stable 
expression only of the genomic RNA and 2.2kb subgenomic RNA (Graff et al., 
2006). This subgenomic RNA started at 5122 and was bicistronic for the 
translation of both ORF2 and ORF3. This model also explains the reading 
frame differences observed for gt4, which contains an extra nucleotide T-insert 
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between 5116/5117 (SAR-55) resulting in a different reading frame for the 
ORF3 start codon. The translation of ORF3 from position 5131 (SAR-55) 
should be the same for all gt1-4. Several other studies supports this model 
through intrahepatic inoculation of unchanged and mutant gt3 swine HEV 
replicons into swine and through secondary structure predictions (Huang et al., 
2007). Another study confirmed the existence of the 2.2kb subgenomic RNA 
and its starting position at 5122 through PLC/PRF/5 cells inoculated with fecal 
suspension containing gt4 or transfected in vitro from a cloned cDNA 
produced from infectious gt3 RNA (Ichiyama et al., 2009). The role of the JR 
secondary structure in viral replication was demonstrated when Huh7-cells 
were transfected with unchanged or mutant JR replicons with reporter genes 
(Cao et al., 2010). The viral negative-strand RNA may act as a template for the 
positive-strand genome and subgenomic RNA synthesis, the former within the 
JR in a primer-independent manner. The JR of negative-sense directed RNA is 
predicted to contain a folded stem-loop structure. Mutations on the predicted 
loop or part of the stem of the subgenomic RNA start site considerably reduced 
or stopped reporter activity. The sequence of the JR therefore play important 
role in HEV replication.  
The ORF2 protein – Viral capsid 
The ORF2 corresponds to nucleotide positions 5145-7125 in the genome. It 
encodes the viral capsid of ~660 amino acids depending on the HEV strain.  
This structural protein is highly immunogenic and is proposed to encapsidate 
the viral RNA and interact with the host cell e.g. while entering into and exit 
from the host cell (Xing et al., 2010). The 111aa N-terminal region appears to 
bind to the 5’ region of the viral RNA (Surjit et al., 2004). This region also 
contains signal sequence, which translocates the ORF2 protein to the 
endoplasmatic reticulum (ER), where it is glycosylated at three conserved 
asparagine sites (137, 310 and 562), (Zafrullah et al., 1999). This is required to 
produce infections virus particles and for efficient propagation, as has been 
shown in cell lines with HEV replicons (Yamada et al., 2009b; Graff et al., 
2008). There is a broad antigenic cross-reactivity between ORF2 proteins from 
known HEV genotypes, which has been demonstrated with western blot and 
antisera using recombinant capsid from various HEV strains including avian 
HEV (Haqshenas et al., 2002).  
The accessory protein ORF3 
There are currently no homologues to the ORF3 in the sequence databases. The 
protein is located at nucleotide positions 5131-5475nt of the HEV genome. The 
small 114aa protein contains two N-terminal hydrophobic (D1 and D2) and 
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two C-terminal proline-rich regions (P1 and P2), (Ahmad et al., 2011). 
Multiple functions have been proposed for this phosphoprotein including 
interaction with host cell proteins associated with immune evasion, cell 
survival promotion (Kar-Roy et al., 2004), acute phase response modulation 
(Chandra et al., 2010; Chandra et al., 2008; Moin et al., 2007) and 
immunosuppression (Surjit et al., 2006; Tyagi et al., 2004). This protein 
appears not to be essential for infection and replication (Emerson et al., 2006), 
but its presence is needed for the virion release from cells (Nagashima et al., 
2011). The phosphorylated form of ORF3 (S71 residue) was shown to interact 
with the non-glycosylated form of the capsid protein (Tyagi et al., 2002). This 
post-translational interaction suggested a regulatory role of ORF3 during virion 
assembly. Substantial sequence diversity of ORF3 has been observed between 
genotypes and even within genotypes, but also within more divergent HEV 
strains found in wild animals e.g. moose HEV (Studies I).    
Viral particle structure  
The capsid protein expressed in mammalian cells was reported as an 74kDa 
unglycosylated and an 88kDa glycosylated forms (Jameel et al., 1996) and it is 
still controversial which form/s build the virion. From 3D structure studies of 
the HEV capsid it is observed that the main structure of the virion shell uses 
two identical capsid proteins (homodimers) as a base for the construction of the 
virion shell. The existence of two different forms of the HEV virus like 
particles (VLPs) have been shown T=1 and T=3 (Figure 2), consisting of 60 
and 180 capsid monomers, respectively. 
Figure 2.Structural representation of T=1 (left), 3HAG (Guu et al., 2009) and T=3 (Right), 3IYO 
(Xing et al., 2010), adapted from the Protein database (PDB), 
http://www.rcsb.org/pdb/home/home.do, (accessed 2015-07-15). 
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These monomers have been shown to form three distinct domains assigned 
shell (S), middle (M) and a protruding (P) domains (Xing et al., 2010; 
Yamashita et al., 2009; Li et al., 2005b). The T3 structure is suggested to be 
the more likely for packaging the HEV virion (Cao & Meng, 2012; Xing et al., 
2010). The structure of the wild type virion has not been resolved and therefore 
still remain unknown (Mori & Matsuura, 2011). The possible existence of two 
types of HEV virions have been suggested, one nonenveloped viron found in 
fecal samples and one enveloped-like virion found in serum. The latter is 
associated with ORF3 and lipids with unknown structure (Yamada et al., 
2009a; Takahashi et al., 2008). These two suggested virion types indicate that 
more studies should be performed. 
1.2.2 Viral life cycle overview  
The life cycle of HEV is largely unknown due to the lack of efficient culture 
systems and small animal models (Ahmad et al., 2011). This has hampered the 
understanding of the HEV pathogenesis and antiviral drug development. HEV 
most likely enters the body orally and the primary site for viral replication is 
believed to be the liver, with the hepatocytes being the most likely cell type to 
be infected (Ahmad et al., 2011). Current knowledge suggest that the structural 
HEV capsid protein binds to cellular receptor/s to start viral entry and initiate 
replication (Figure 3A). The specific cellular receptor for HEV is still 
unknown, but through ORF2 binding studies; the ORF2 C-terminal region was 
suggested to bind to heat shock cognate protein 70 (HSC70), (Parent et al., 
2009), a member of the heat shock proteins acting as chaperons. Heparan 
sulfate proteoglycans (HSPG) has also been suggested as viral receptor on the 
cell surface (Kalia et al., 2009). A receptor-dependent clathrin-mediated 
endocytosis (Figure 3B) has been demonstrated to be involved in the HEV 
particle entry (Kapur et al., 2012).  
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Figure 3. A schematic HEV replication from entry to egress from the host cell. A-C) Binding of 
HEV virion to putative host receptors. D) Release of HEV genome enabling translation of ORF1 
protein, which most likely uses the available positive sense HEV genome as template for negative 
sense synthesis E). This is in turn a template for the production of new positive sense HEV 
genomic RNA, including a smaller subgenomic genome, which ORF2 or ORF3 are translated 
from, see G). H) Particle assemble initiates with the binding of ORF2 to the genomic RNA and 
interaction with ORF3. (I-J) The virions are transported to the plasma membrane for the release of 
the membrane-associated HEV particles. K) The virion will lose the membranes when passed 
through the digestive system, ready for infecting a new host. This is reproduced from (Kenney & 
Meng, 2015), with permission from the publisher Taylor & Francis.  
Once inside the cell, the capsid is thought to interact with heat shock protein 90 
(HSP90) and glucose-regulated protein 78 (Grp78) for the intracellular 
transport and uncoating (Yu et al., 2011; Zheng et al., 2010), (Figure 3C). Like 
cellular caped mRNA, the cap structure in the 5’UTR terminal of the HEV 
genome recruits 40S ribosomal subunit to start cap-dependent translation of 
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NS-polyprotein ORF1 (Figure 3D). It is thought that the viral RdRp of the 
ORF1 associates with the host ER through a predicted transmembrane domain 
corresponding to residues 4449-5109 to begin replication of the viral genome 
(Rehman et al., 2008). The replication process most likely involves synthesis 
of negative-sense RNA (Figure 3E) which has been detected in tissues from 
HEV infected animals (Varma et al., 2010; Nanda et al., 1994). This most 
likely occurs when the RdRp binds to the secondary structure of the viral 3’ 
UTR genome, which initiates the synthesis of negative sense RNA genome. 
This template is then used for the synthesis of full genome and the 2.2kb 
SgRNA (Figure 1 and Figure 3F), (Cao & Meng, 2012).  
This enables the translation of more ORF1 proteins, and capsid protein 
from ORF2 and the small ORF3 protein translation from the bicistronic 
subgenomic RNA (Figure 3G), or the HEV genome is encapsidated with help 
from ORF2 (Ahmad et al., 2011; Graff et al., 2006), (Figure 3H). Assembly 
and release of the HEV virions are still poorly characterized. However, it has 
been shown that the ORF2 protein can bind the viral RNA through a 76-nt 
region at the 5’ end of the HEV genome and most likely package it through the 
assembly of progeny virions (Surjit et al., 2004), see Figure 3H. The N-
terminal end of ORF2 also contain a signal sequence, which translocates the 
ORF2 protein to the endoplasmatic reticulum (ER), where it is glycosylated at 
three conserved asparagine sites (137, 310 and 562), (Zafrullah et al., 1999), 
see Figure 3I. The ORF3 protein is thought to be involved in a later step 
through an amino acid motif PSAP, associated with protein interactions, 
important for the release (Figure 3I-J) of the membrane-associated HEV 
particles from infected cells (Nagashima et al., 2011). It has been shown that 
this virion form that circulates in blood has stealth properties masking HEV 
from antibodies targeting virions without membrane, which also can be seen 
with hepatitis A virus (HAV), (Feng & Lemon, 2014). The potential membrane 
surrounding the released virions is most likely cleaved/removed in the gut 
(Figure 3K) when the virus is shed with feces (Okamoto, 2013).   
1.2.3 Continous discovery of new HEVs require an updated HEV classification 
Recently, several HEV related strains have been detected in addition to gt1-4 
(Figure 4 and Figure 5). A common property of these HEV-related strains are 
the highly divergent genomes as compared to gt1-4, despite the characteristic 
genomic organisation with three HEV ORFs. Their genetic classification, and 
cross species and zoonotic potential need to be further investigated.  
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With the continuous discovery of new HEVs, several proposed classification 
strategies have been presented (Johne et al., 2014a; Meng, 2013; Smith et al., 
2013a). However, a consensus HEV classification was very recently proposed 
from the members of the ICTV Hepeviridae Study Group, and the criteria was 
based on phylogeny and host range (Smith et al., 2014). It is proposed that all 
HEVs are placed into two genera instead of one: Orthohepevirus with four 
species (A-D) and Piscihepevirus with a single species Piscihepevirus A 
(Figure 5). 
 
Figure 5 Phylogenetic tree of selected full HEV genomes and their classification according to 
Smith et al., (2014). The moose HEV is currently unassigned HEV variant and is described in this 
thesis.   
 
Species like Orthohepevirus A and Orthohepevirus C are proposed to contain 
genotypes, seven and two respectively. The members of Orthohepevirus A 
consist of genotypes 1-7 (Smith et al., 2014). The species where these 
genotypes can be found are human (gt1-4), swine (gt3-4), wild boars (gt3-6), 
rabbit (gt3), deer (gt3-4), mongoose (gt3), camel (gt7), and rat and ferret, 
(Figure 5). The zoonotic potential is still unknown for the more divergent gt5-
7. Orthohepevirus B contain viruses found in chickens and was the first highly 
divergent genome detected. Since then it has been associated with the avian 
disease hepatitis-spenomegaly syndrome (HSS) in USA (Haqshenas et al., 
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2001) or big liver and spleen disease (BLSV) in Australia, (Payne et al., 1999) 
which can have an important economic impact for the affected breeder. About 
80% nucleotide sequence identity was found between HSS and BLSV HEV 
strains, showing that they are variants of the same virus (Guo et al., 2006; 
Huang et al., 2004). Orthohepevirus C has two members found in rat (HEV-
C1) and ferret (HEV-C2), and Orthohepevirus D contain bat virus (Figure 5). 
Partial sequences from other possible members of the family was recently 
identified in mink (Krog et al., 2013) with similarity to HEV in ferret, fox and 
rat (Thiry et al., 2015). The HEV identified in moose is still unclassified. 
Studies I-II of this thesis discuss the classification issues, describe the 
investigation of the HEV prevalence in Swedish moose, and discuss the 
zoonotic perspective of moose HEV, which is still unclear. Hepeviridae is a 
dynamic and expanding family of vertebrate viruses and a flexible consensus 
classification is therefore needed. 
1.2.4 HEV subtype classification and genotypes 1-4  
Although not officially recognized by ICTV, the most widely used gt1-4 
subtyping classification suggest a total of 24 subtypes (1a-e, 2a-b, 3a-j, and 4a-
g), (Lu et al., 2006). This was based on 49 complete genomes and different 
subgenomic sequences, and individual subgrouping was assigned to nucleotide 
differences of 12-18% for e.g. gt3 and gt4. But recent studies, have found 
inconsistencies mainly concerning the reliability of the subtype separation and 
the inability to support newly detected and highly divergent HEV variants 
found in animals (Oliveira-Filho et al., 2013; Smith et al., 2013a). Despite 
these limitations, classification under genotype level is still very useful and 
important for both clinical and epidemiological studies e.g. tracing currently 
circulating strains in the population (Widén et al., 2010; Norder et al., 2009), 
including from studies II and III.  
Genotype 1 and 2 (gt1-2) 
Genotype 1 (gt1) dominates in Asia and Africa, genotype 2 (gt2) includes 
strains from Mexico and Africa, and both of these genotypes have only been 
found in humans (Kamar et al., 2012a). Both genotypes are responsible for 
large outbreaks and epidemics in developing countries or overcrowded areas 
such as in refugee camps with poor sanitary conditions and drinking water 
contaminated with fecal matter (Kamar et al., 2012a).  
Genotype 3 (gt3) 
Swine HEV assigned as genotype 3 (gt3) was first discovered in the USA, 
1997. Further studies showed that this agent was highly prevalent in swine and 
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raised public health concerns for zoonotic infections (Meng et al., 1997). It 
turned out later that gt3 was not a coincidental discovery, and that it was 
widely prevalent in the world, especially associated with swine and wild boar. 
This genotype is also responsible for most autochthonous HEV infections in 
Europe, USA, and Japan (Kamar et al., 2012a). Gt3 has been detected in many 
animal species reflecting its cross-species infection ability. Evidence of 
zoonotic transmission like highly similar gt3 genomic sequences from the 
patient and left overs of food products made from swine and deer, have been 
demonstrated (Li et al., 2005a; Tei et al., 2003). From a phylogenetic 
perspective, gt3 is divided into two main groups assigned as 3.I and 3.II 
(Widén et al., 2010; Norder et al., 2009). Ten subtypes (3a-j) are further 
proposed (Lu et al., 2006) and are distributed within 3.I or 3.II group. It 
appears that gt3c, gt3e and gt3f are the most frequent subtypes both in humans 
and porcine in European countries (Widén et al., 2010; Legrand-Abravanel et 
al., 2009; Norder et al., 2009). Previous studies have shown the subtype gt3f 
appears to dominate in Sweden (Widén et al., 2010; Norder et al., 2009). 
Currently, only one complete genome of a Swedish swine gt3f has been 
published (Xia et al., 2008), but study III expand this list with six near 
complete gt3f genomes from porcine HEV, characterised from a zoonotic, 
recombinant and virulence perspective. Swedish deer species, including the 
largest deer, the moose have never been investigated for HEV infection before 
and the zoonotic risk from consumption of deer indicated by other studies 
motivated the work presented in papers I-II and IV.  
Rabbit HEV a distant member of gt3 
In 2009, a novel HEV was found in rabbits (Zhao et al., 2009) and since then it 
has been discussed whether the rabbit HEV belong to gt3 or not. With 85% 
sequence identity with each other and ~73-79% identity with gt1-4, raised 
question whether if it should be placed in its own genotype or as a distantly 
related gt3 member. However, it is becoming more acceptable to place the 
rabbit HEV in the gt3, since it according to the phylogenetic studies, forms a 
distant third gt3 subgroup (Smith et al., 2014).  
Genotype 4 (gt4)  
Genotype 4 (gt4) was discovered in 1999 from patients in China. The first 
whole genome was sequenced in the year 2000. This genotype is mostly 
prevalent in Asia, where it has been recovered from both in pigs and humans 
with high genetic similarity indicating zoonotic transmission (Liu et al., 2012; 
Wang et al., 2000; Wang et al., 1999). However, gt4 have also been found in 
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wild boar (Sato et al., 2011) and some cases associated with zoonosis (Kim et 
al., 2011).  
The dominance of gt1 infections in China appears to have shifted over the 
last 25 years, where gt4 has overtaken the gt1 in number of isolated strains (Liu 
et al., 2012). This may result from the fact that sanitary conditions have 
improved and food-borne replaced water-borne transmission generating a 
genotype switch. However, it is important to remember that the actual gt4 
status before 1999 was not investigated because molecular studies was focused 
on large epidemics and not on sporadic cases caused by gt4 (Liu et al., 2012).  
Gt4 has recently also been observed in Europe (France, Belgium and 
Denmark), both in humans and swine, raising the question if gt4 was 
introduced to European domestic swine through imported swine meat from 
Asia and suggest that gt4 is already established in Europe (Bouamra et al., 
2014; Colson et al., 2012). Like for gt3, other animal species besides swine 
have been observed to be gt4-infected, like sheep and yak (Wu et al., 2015; 
Midgley et al., 2014; Xu et al., 2014; Wang & Ma, 2010), but these results 
need to be confirmed by other laboratories as well. 
1.3 Clinical outcome  
This section is divided into several sub sections, starting with the introduction 
of the clinical manifestations of HEV in humans and animals. The 
pathogenesis of HEV and other clinical manifestations of HEV infection is 
only partially understood. 
1.3.1 Clinical manifestation in humans 
Whether infected through larger epidemics or autochthonous sporadic 
transmission, clinical symptoms can occur, which is important for the 
diagnostic identification of HEV. The clinical hepatitis E infection in humans 
is often near undistinguishable from hepatitis A virus (HAV) infection. It may 
cause self-limiting acute infection (AH), asymptomatic infection with non-
existent and mild symptoms, or fulminant hepatitis (FH). The most typical 
clinical signs are: elevated transaminases, jaundice, abdominal pain, headache, 
fever, nausea/vomiting, anorexia, pruritus and hepatomegaly (enlarged liver), 
(Aggarwal, 2011). The incubation period from the exposure of HEV to 
development of clinical signs of infection ranges from two weeks to two 
months (Purcell & Emerson, 2008).  It is believed that the liver is the main 
target organ, but how HEV reaches the liver is unknown and other extra-
hepatic sites where HEV replication occurs is still being investigated. But once 
it has reached the liver, the virus replicates in the cytoplasm of hepatocytes, 
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passed in the bile and then being shed in feces. Both viremia and fecal 
shedding are detected before the onset of disease. This is mainly indicated with 
elevated alanine aminotransferase (ALT), with peak levels during the acute 
phase, thereafter the ALT levels will gradually return to normal levels. The 
humoral response makes its presence in parallel with elevated ALT in form of 
increased anti-HEV IgM followed IgG, which may remain circulating in the 
body up to 14 years (Emerson & Purcell, 2003). A general summarized 
overview of the course of HEV infection is shown in Figure 6. 
 
 
Figure 6. An overview of the HEV infection through time, showing the virus presence at different 
locations and serological response. This is reproduced (Dalton et al., 2008a) with permission by 
Elsavier.  
Although most HEV infection are self-limiting, there is still mortality rates up 
to 0,5-4%  during outbreaks (Aggarwal, 2011). however, the mortality rate is 
increased when it comes to certain patients groups such as pregnant women 
and patients with other liver diseases (Aggarwal, 2011). The comparable few 
reported human clinical HEV cases is contradictory to the in general high HEV 
seroprevalence 5-53% observed in many countries (Kamar et al., 2012a; 
Mansuy et al., 2011; Guo et al., 2010; Olsen et al., 2006).  
This is especially true for developed countries with good sanitary standard, 
where the high seroprevalence corresponds only to a small fraction of the total 
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reported HEV infections, and this may be due to low infectious dose causing 
subclinical HEV infections (Kamar et al., 2012a). 
Pregnancy and HEV infection 
Both epidemic and sporadic forms of hepatitis E, especially in hyperendemic 
areas with gt1-2, are characteristically associated with an increased mortality 
rate up to 25% in the third trimester in infected pregnant women (Kamar et al., 
2012a). This appears not be common for gt3-4 although there has been some 
documentation with acute hepatitis (Anty et al., 2012), but not with mortality 
as outcome. The actual mechanism of the high mortality of HEV infection 
during pregnancy is still unclear and is constantly under debate. The pregnancy 
status itself is characterized with maternal immune tolerance toward the fetus, 
so it can survive but still being able to fight threatening infections. One theory 
of the pathogenesis associated with HEV is that the hormonal changes in the 
pregnant woman shift immune response profile during the trimester period 
from Th1 to Th2 profile (Navaneethan et al., 2008; Pal et al., 2005). Higher 
viral loads were also observed in pregnant women compared to women with no 
pregnancy (Borkakoti et al., 2013). Other FH cases caused by gt1 in India, 
have been shown infected with strains with amino acid mutations, suggesting 
the existence of different virulent HEV strains (Mishra et al., 2013). The 
genetic composition of the host may also be involved in disease outcome. HEV 
can also be transmitted vertically, from mother-to-foetus and may cause high 
mortality in young infant for unknown reasons. This is exemplified from a 
report from India, where 15 of 19 infants born from HEV infected mothers, and 
six of the 19 infants died whereas 9 managed the infection (Khuroo & Kamili, 
2009). 
Chronic hepatitis E and HEV infection with pre-existing liver disease 
A growing number of studies highlight that HEV can cause chronic infection in 
immunosuppressed patients, who can rapidly develop fibrosis and cirrhosis and 
subsequent liver failure if not treated (Fujiwara et al., 2014). Chronic HEV 
infection has therefore often been observed in organ transplant recipients (e.g. 
liver, heart and kidney), (Fujiwara et al., 2014) and in HIV positive individuals 
(Hajji et al., 2013; Dalton et al., 2009). Common with these studies is that it 
has been reported from developed countries in Europe and USA and all 
infecting strains have been gt3 (Fujiwara et al., 2014). Several approaches are 
available to treat chronic infection successfully; as dose reductions of 
immunosuppressive therapy, treatment with the antiviral drug ribavirin and 
administrated pegylated interferon alpha (Kamar et al., 2011b; Haagsma et al., 
2010; Mallet et al., 2010). Individuals with pre-existing liver disease, may also 
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develop higher frequency of clinical manifestations and liver damage when 
HEV infected (Radha Krishna et al., 2009; Ramachandran et al., 2004; Hamid 
et al., 2002).  
Extra-hepatic manifestations 
During the HEV infection, extra-hepatic manifestations could occur which may 
case diagnostic difficulties for the clinician. It is therefore important to 
highlight these manifestations because HEV is most probably an under-
diagnosed pathogen.  
A recent review identified 25 studies of HEV infections associated with 
neurological problems (Cheung et al., 2012). The most frequent were Guillain-
Barré syndrome and brachial neuritis. Another study found that 5.5% of 
patients with locally acquired HEV infection developed neurogical symptoms 
(Kamar et al., 2011a). One renal transplant patient with chronic HEV infection 
was diagnosed with complication associated with both the central and 
peripheral nervous system (Kamar et al., 2010). A gt3 was isolated from the 
cerebrospinal fluid and its genomic sequence was different from the gt3 
variants in the serum. Other less frequent extra-hepatic manifestations are renal 
complications, thrombocytopenia and pancreatitis (Kamar et al., 2012b; 
Aggarwal, 2011). 
1.3.2 Clinical outcome in animals  
The pathogenesis of HEV has been studied only in swine. Domestic swine 
worldwide are commonly infected by HEV, with gt3 and/or gt4, and are most 
frequently detected in piglets 2-4 months of age, whereas younger or older are 
less frequently infected (Widén et al., 2010; Meng et al., 1997). This is due to 
the protection caused by the maternal immunity in very young piglets (de Deus 
et al., 2008a; Meng et al., 1997), while older swine have already established 
HEV immunity (Williams et al., 2001; Yoo et al., 2001; Hsieh et al., 1999). It 
is still unclear how the virus enters the swine and reach the liver, which is 
suspected to be the primary replication site (Williams et al., 2001; Meng et al., 
1997). Swine appear not to show any signs of clinical illness during the HEV 
infection, however mild liver lesions have been reported (Halbur et al., 2001; 
Meng et al., 1997). In one experimentally HEV infected swine, the negative 
HEV RNA strand as an indicator of HEV replication was detected in extra-
hepatic tissues such as: tonsils, lymph nodes, spleen, stomach, kidneys, lungs, 
both small and large intestine and salivary glands up to 20-27 days post-
infection (pi) (Williams et al., 2001). Similar extra-hepatic sites for HEV 
replication have also been reported in other studies (de Deus et al., 2008a; Choi 
& Chae, 2003). During experimental HEV infection, viral RNA has been 
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detected in feces earlier than in the bile in about tenfold higher quantities. This 
finding suggested pre-amplification of HEV taking place first in the 
gastrointestinal tract followed by spread to liver and then followed by viremia 
(Meng et al., 1998a; Meng et al., 1998b). The viremia phase may last for about 
2 weeks, but the virus can be detected in feces for additional 3-50 days pi and 
seroconversion occurs 2-3 weeks pi (Lee et al., 2009; Halbur et al., 2001; 
Williams et al., 2001). Wild boars are also frequently infected with HEV and 
are consider as an additional HEV reservoir, see study IV, (Widén et al., 2010). 
Like domestic swine, infection of wild boar also appear to have an 
asymptomatic outcome (Schlosser et al., 2014).  
The only HEV type to cause more severe symptoms in animals is avian 
HEV associated with hepatitis-spenomegaly syndrome (HSS) and big liver 
spleen disease (BLS) (Billam et al., 2005). The disease in chickens is 
characterized by enlarged liver and spleen with histological changes in form of 
hepatic necrosis and haemorrhages leading to increased mortality among egg 
laying chickens and broilers, and 20% reduction of egg production (Sun et al., 
2004). This may cause substantial economic loss. Except for avian HEV, no 
other serious hepatitis E related disease in animals have been reported. The 
clinical outcome of HEV infection in moose is discussed in study II.    
1.4 Epidemiology 
1.4.1 General epidemiology  
WHO estimates that there are globally around 20 million people infected 
annually with HEV resulting in approximately 56,600 deaths, however the 
numbers are most likely to be much higher. HEV have from the past to present 
haunted the human population with large outbreaks. About 70 outbreaks from 
the year 1955 have been documented (Perez-Gracia et al., 2014), and the 
largest and most recent outbreaks can be found in Table 1. 
The HEV infection pattern can roughly can be divided into three 
geographically degrees of HEV endemicities: hyperendemic, endemic and not 
endemic/lack of data, (Figure 7). The geographical distribution of HEV 
genotypes is complex and constantly changing (Figure 7). Gt1-2 only infects 
humans and causes both infections and large waterborne outbreaks, mostly 
occurring in developing countries located in tropical and subtropical areas, 
assigned as hyperendemic HEV regions (Ruggeri et al., 2013). Large HEV 
outbreaks have also occurred in the past and gt1-2 are the most likely 
genotypes behind these events, Table 1. 
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Figure 7. The worldwide HEV infection distribution illustrating A) the locations of the three 
endemic grade of the infection in different colours. B) from a genotype perspective. The colours 
for each country represent the most frequent HEV genotypes from human and animals (frequently 
from swine). The image was adapted from (Ruggeri et al., 2013) with permission from Professor 
Fabio Ostanello.       
Gt3-4 not only infects human but also a wide range of animals that therefore 
could possible act as virus reservoirs for human infection. These genotypes are 
frequently behind autochthonous sporadic HEV cases in developed countries in 
America, Europe, Oceania and Asia (Ruggeri et al., 2013). Gt4 is common to 
Asia, but now appears to be spreading in Europe (Midgley et al., 2014; 
Jeblaoui et al., 2013; Colson et al., 2012).  
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Table 1. List of some of the largest and most recent outbreaks of hepatitis E 
and number of cases in each outbreak.  
CONTINENT YEAR COUNTRY CASES REFERENCE 
Africa     
 1988–1989 Somalia 11,413 (Bile et al., 1994) 
 2007–2008 Uganda >10,535 (Teshale et al., 
2010a) 
     
 2012 Kenya 223 (UNHCR, 2012a) 
 2013 Sudan 3991 (UNHCR, 2012b) 
 2014-15 Ethiopia 1117 (Browne et al., 
2015) 
Asia     
 1955 India 29300 (Arankalle et al., 
1994) 
 1973–1974 Nepal 10,000 (Khuroo, 1991) 
 1976–1977 Myanmar/Burma 20,000 (Khuroo, 1991) 
 1978–1979 India 20,000 (Khuroo, 1991) 
 1979–1980 India 6000 (Khuroo, 1991) 
 1981–1982 Nepal 4337 (Khuroo, 1991) 
 1981–1982 India 15000 (Khuroo, 1991) 
 1985 Turkmenistan 16,175 Albetkova et al., 
2007 
 1986-1988 China 120,000 (Zhuang et al., 
1991) 
 1987 Nepal 7405 (Shrestha, 2006) 
 1990 India >3000 (Arankalle et al., 
1994) 
 2004 Indonesia 49 (World Health, 
2005) 
 2012 India >4000 (News, 2012) 
     
 
It should be noted that the HEV prevalence varies between and within 
countries and may reflect the population studied, the time when the study was 
performed and the sensitivity of the assay used for the study. The actual HEV 
seroprevalence reported from many studies may differ.   
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1.4.2 Epidemiology of Human HEV infection 
Hyperendemic regions- with high disease prevalence  
In the hyperendemic regions, the disease is caused by gt1-2, usually associated 
with contaminated waterborne outbreaks transmitted via the classical fecal-oral 
route that may affect large a part of the population simultaneously, and are 
often reoccurring. In some regions the outbreaks are seasonal because of 
monsoon or flooding events e.g. Nepal (Shrestha, 2006). From a subtype 
perspective, subtype gt1a, gt1b and gt1c are prevalent in Asia, while gt1d and 
gt1e are localised in Africa (Lu et al., 2006). Large gt1-2 outbreaks are 
signified with mortality rate up to 25% in the third trimester of pregnant 
women (Kamar et al., 2012a). An age depended HEV seroprevalence in 
developing countries shows that most children under the age of 10 years have a 
low seroprevalence opposite to hepatitis A, where children over 10 years 
frequently have antibodies against this virus (Emerson & Purcell, 2003; 
Arankalle et al., 1995). The seroprevalence increases dramatically (up to 40%) 
between the ages of 15-30 years old (Kamar et al., 2014; Emerson & Purcell, 
2003). Unlike several other infections with fecal-oral transmission, person-to-
person transmission of HEV is considered uncommon (Aggarwal & Jameel, 
2011). Sporadic cases caused by gt1-2 observed in travellers/guest worker 
returning from hyperendemic regions are well documented in the literature 
(Norder et al., 2009).  
Regions with low HEV disease endemicity  
Numerous studies have demonstrated autochthonous hepatitis E detected in 
patients who had never travelled to foreign countries in Europe, North 
America, New Zeeland and Japan (Drobeniuc et al., 2013; Dalton et al., 2008b; 
Dalton et al., 2007a; Dalton et al., 2007b; Mansuy et al., 2004; Mizuo et al., 
2002) and study IV. This has changed the view regarding HEV as a disease 
limited to developing countries or to travellers returning from such areas. 
Several studies have reported high HEV seroprevalence (5-53%) (Kamar et al., 
2012a; Mansuy et al., 2011; Guo et al., 2010; Olsen et al., 2006). HEV RNA 
has been identified in one out of 4,500 German and one out of almost 8,000 
Swedish healthy blood donors (Baylis et al., 2012). It seems that wide spread 
HEV infections are occurring silently as subclinical infections, while clinical 
disease associated with HEV only constitute the top of an iceberg (Kamar et 
al., 2012a; Emerson & Purcell, 2003). There can also be a wide geographic 
variation in seroprevalence and incidence within a country e.g. the 
seroprevalence is about four times higher in southern France compared to 
northern France (Boutrouille et al., 2007). Similar north-south pattern was also 
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seen in the UK, with seroprevalence of 16% in southwest England while only 
4.6% in Edinburgh and 12% in the rest of England (Cleland et al., 2013; Beale 
et al., 2011; Dalton et al., 2008b). The cause for this seroprevalence variation 
is unclear and may reflect the use of different assays or different regional 
habits. In contrast with developing countries, autochthonous hepatitis E is 
associated with the zoonotic gt3-4 and the transmission route for many HEV 
cases is unknown. The mortality rate seen in gt1-2 is higher than with gt3-4 for 
pregnant women, although there have been documented cases with acute 
hepatitis caused by gt3 (Anty et al., 2012). Another dissimilarity is that elderly 
males (mean age of ~60 years; male/female ratio, >3:1) are overrepresented 
among clinical hepatitis E cases (Drobeniuc et al., 2013; Dalton et al., 2008b; 
Dalton et al., 2007a; Mansuy et al., 2004). The reason for this finding remain 
largely unsolved, but professional and/or life style and gender-related 
physiological factors may contribute. So what causes the general high 
seroprevalence in the population? The high prevalence indicate that other 
sources of infection than food may play a role. 
1.4.3 Epidemiology of animal HEV infection 
As stated by WHO, about 75% of the new diseases that has affected humans 
over the past ten years have been caused by pathogens originating from 
animals or from products of animal origin (WHO, 2014). The HIV, SARS and 
now MERS, all with animal origin are good examples of threats to the public 
health. From a one health perspective, the continuous screening and 
characterization of viruses with epidemic potential and detection of new 
viruses should therefore be prioritized and early detection may contribute to 
stop new outbreaks in an early stage. The discovery of HEV in animals have 
significantly broaden our concept of the host range and diversity of HEV. The 
detection of HEV antibodies in several animal species (Thiry et al., 2015; 
Pavio et al., 2010) indicate that new HEV like viruses still remain to be 
discovered. The zoonotic potential of many of the recently discovered novel 
animal HEVs still remains unknown and their prevalence is under 
investigation.  
Domestic swine, wild boar and rabbit  
The gt3-4 have been found to be highly prevalent in swine and wild boar 
worldwide. Factors affecting the prevalence rates may be geographical region, 
sample type, living pattern, age of the animals and the use of different assay 
brands.  
HEV subtypes gt3a and 3b dominates in the US and Japan and is clearly 
distinguished from 3f, 3c and 3e which mainly circulates in Europe in both 
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humans and swine (Izopet et al., 2012; Luciano et al., 2012; Bouquet et al., 
2011; Renou et al., 2011; Widén et al., 2010; Legrand-Abravanel et al., 2009; 
Norder et al., 2009; Lu et al., 2006). However, a molecular tracing study based 
on numerous full-length of gt3 from acute hepatitis E patients, swine and wild 
boar suggested that subtype gt3e was introduced from Europe to Japan through 
importation of swine in the 1960s (Nakano et al., 2013). The same study also 
proposed that a movement of subtype 3e from swine to wild boar had occurred 
in Japan. Close geographically specific genetic relatedness among gt3 and gt4 
HEV strains from humans and swine have been observed in Europe and Japan 
(Forgach et al., 2010; Widén et al., 2010; Fogeda et al., 2009; Norder et al., 
2009; Reuter et al., 2009; Dalton et al., 2007b; Yazaki et al., 2003; Schlauder 
et al., 1998). An interesting study from Sweden on HEV strains recovered from 
piglets in twelve farms, wild boars from nine counties and infected humans 
showed that piglets in Swedish farms were infected with strains distinct for 
each farm (Widén et al., 2010). Most HEV strains from Swedish swine and 
wild boars belong to subtype 3f, which is the most common subtype circulating 
in France, the Netherlands and Spain (Kaba et al., 2009; Legrand-Abravanel et 
al., 2009; Peralta et al., 2009; Rutjes et al., 2009; van der Poel et al., 2001); All 
Swedish HEV strains seemed to form clades in the phylogenetically tree 
according to geographical origin, country- and even county-specific and 
allowed for the identification of the geographical origin of HEV strains (Widén 
et al., 2010).  
Beside swine, wild boar also act as HEV reservoir. The subspecies Sus 
scrofa is prevalent in Europe, while the two phylogenetically different 
subspecies Sus scrofa leucomyxtas and Sus scrofa riukiuanus are prevalent in 
Japan (Watanobe et al., 1999). The HEV prevalence in wild boar have been 
evaluated in several European countries and Japan, with seroprevalence 
ranging from 8 to 43% and HEV RNA prevalence between 2 and 68%, see 
study IV, (Widén et al., 2010), Germany (Schielke et al., 2009), France 
(Carpentier et al., 2012), Spain (Boadella et al., 2012; de Deus et al., 2008b), 
the Netherlands  and Italy (Martelli et al., 2008), but also in Japan (Li et al., 
2005a; Masuda et al., 2005; Nishizawa et al., 2005; Sonoda et al., 2004; 
Takahashi et al., 2004a; Tamada et al., 2004; Matsuda et al., 2003) and 
Australia (Chandler et al., 1999). In contrast to HEV infection usually 
occurring in 2-4 months old piglets with short asymptomatic self-limiting 
course (Widén et al., 2010; Meng et al., 1997), HEV positive wild boars were 
shown to be infected in several age classes from 4 months up to 2 years old or 
even older, study IV, (de Deus et al., 2008b; Nishizawa et al., 2005; Sonoda et 
al., 2004). The difference in HEV prevalence profile in relation to age may be 
that wild boar live in smaller family groups in larger territories and not as 
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swine with a large population confined to a limited area facilitating HEV 
transmission. Additional explanation indicates that the HEV infection in the 
animals may become chronic or they may be re-infected, if they have not 
developed protecting immunity, maybe due to co-infection with other agents. 
Lack of anti-HEV responses and prolonged HEV persistence were detected in 
some wild boar experimental infected with HEV (Schlosser et al., 2014). Most 
of the conducted HEV prevalence studies have observed that infected wild 
boars appeared to be healthy, as has been shown for infected domestic swine 
(Schlosser et al., 2014; Meng et al., 1998a; Meng et al., 1997). The high HEV 
prevalence and subclinical nature of HEV in the animals are worrying because 
of the possible risk of transmission either through direct contact with wild boar 
or by consumption of undercooked meat or organs. Evidence for such zoonotic 
pathway have been reported on several occasions, especially from Japan (Li et 
al., 2005a; Masuda et al., 2005; Takahashi et al., 2004a; Tamada et al., 2004; 
Matsuda et al., 2003). Recent studies from Japan also found unrecognized 
novel HEV genotypes in wild boars, suggested as gt5 and gt6 (Sato et al., 
2011; Takahashi et al., 2011). Their zoonotic ability still remains unclear and 
further studies are needed.     
Moongoose, rabbit and Deer  
Molecular and serological evidence of HEV infection in the family of Cervidae 
(deer) has been reported for several deer species like Sika deer (Cervus 
nippon), Red deer (Cervus elaphus) and Roe deer (Capreolus capreolus) (Di 
Bartolo et al., 2015; Choi et al., 2013; Boadella et al., 2010; Forgach et al., 
2010; Rutjes et al., 2010; Reuter et al., 2009; Tomiyama et al., 2009; Matsuura 
et al., 2007; Takahashi et al., 2004a). The HEV seroprevalence can be 
estimated to 2-30% and HEV RNA prevalence around 30%. Both gt3 and gt4 
have been reported, however the HEV strain detected in moose is not a gt1-4 
HEV variant and it is further investigated in studies I-II & IV. The high HEV 
prevalence in the Cervidae family suggest an additional important HEV 
reservoir linked to consumption of deer meat or dear related products, and 
transmissions to humans have also been documented (Choi et al., 2013; 
Takahashi et al., 2004a; Tei et al., 2003).  
The prevalence of HEV infected moongoose in Japan is estimated to 8-21% 
and a full genome of this strain demonstrated that it belong to gt3, related to a 
swine HEV strain (Li et al., 2006; Nakamura et al., 2006). Cross-species 
transmission to other animals or humans has not been documented, but it is 
highly suspected that mongoose HEV is zoonotic due to its genetic similarity 
to other gt3 strains.   
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The HEV strains found in rabbit are considered distantly related to gt3 
(Smith et al., 2014) and appear to be prevalent in farmed rabbits with 
seroprevalence of 7-57% and HEV RNA is found in 7-16% (Cossaboom et al., 
2011; Geng et al., 2011; Zhao et al., 2009). A study from France has shown 
sequences closely related to rabbit HEV in humans, which suggests rabbits as a 
possible viral reservoir for human infections as well (Izopet et al., 2012).  
Fox, Rats, Ferret, mink, fish and bats 
Rats and bats are known to carry several pathogens, which can be transmitted 
to humans, but although HEV was detected in these animals, they exhibited a 
highly divergent genome sequence compared to gt1-4. Antibodies to HEV have 
been detected with seroprevalence up to 80% among wild rats, like black rat 
(Rattus rattus), cotton rat (Sigmodon hispidus) and Norwegian rat (Rattus 
norwegicus),  (Hirano et al., 2003; Arankalle et al., 2001; Favorov et al., 2000; 
Kabrane-Lazizi et al., 1999a). However, none of the studies recovered the viral 
genome and it was not until 2010 that the cause of seropositivity was detected 
using nested broad spectrum RT-PCR. A highly divergent HEV with 50-60% 
similarity to avian and human HEV strains respectively, was recovered from 
fecal samples of wild Norwegian rats from Germany and later a full genome 
was achieved (Johne et al., 2010a; Johne et al., 2010b). Subsequently, several 
rat HEV strains have been isolated from wild rats from other regions of 
Germany, but also from France, USA, China, Indonesia, Denmark and 
Vietnam (Mulyanto et al., 2014; Widen et al., 2014; Li et al., 2013a; Li et al., 
2013b; Wolf et al., 2013; Johne et al., 2012). This divergent Rat HEV is 
suggested to be classified in the species Orthohepevirus C (Smith et al., 2014). 
HEV sequences related to Rat HEV was detected in Asian musk shrews which 
also shared the environment with wild rats in China (Guan et al., 2013). A 
recent study used several rat liver tissues and detected a gt3 like HEV (Lack et 
al., 2012). The same year, HEV was also detected in feces in 9.3% in pet 
ferrets that appeared to be clinically healthy. The genome was related to rat 
HEV (Raj et al., 2012). Recently in 2013, partial genome sequence of HEV 
variant genetically related to ferret was found in four farmed mink from 
Denmark (Krog et al., 2013). The same year, additional genomic HEV related 
fragments related to the Orthohepevirus C species were found in feces of two 
foxes, but this finding may have been due to consumption of rodents (Bodewes 
et al., 2013). 
A virus infecting and causing disease in trout was identified in 1988 and 
named cutthroat trout virus, CTV (Hedrick et al., 1991). About twenty years 
later, the whole genome was sequenced and its genomic organization was 
found similar to HEV (Batts et al., 2011). Due to the high sequence diversity 
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compared to other current HEVs it was suggested as a sole member in the 
genus Pischihepevirus in the Hepeviridae family (Smith et al., 2014).  
A bat HEV study was performed in 2012 on 3,869 bat stool and serum 
samples from 85 bat species across five continents. HEV was detected in three 
bat families (Hipposideridae, Vespertilionidae and Phyllostimidae) (Drexler et 
al., 2012). The same study also screened for bat HEV in 90,000 pooled human 
sera from blood donors/patient sera from Cameroon and Germany with 
negative result indicating that there is still no evidence for bat HEV 
transmission to humans.    
Other recently identified HEVs  
The HEV seroprevalence in sheep from eight Chinese counties was 29% (Wu 
et al., 2010). A subsequent study for the identification of HEV like virus in 
sheep revealed a HEV seroprevalence of 35% and partial sequencing of ORF2 
revealed a HEV RNA prevalence of 5.3%. The sequencing of the strains 
identified a gt4 variant (Wu et al., 2015). The HEV seroprevalence of 58% in 
butchers was also studied and was suggested that sheep may be a source for 
HEV transmissions in humans. Several studies have demonstrated HEV 
prevalence in cattle (6.3%), (Zhang et al., 2008). However, only one study 
from China has genetic information of the infecting strains, of which a 189nt 
ORF2 fragment was sequenced from eight cow feces samples, and shown to 
belong to the gt4 group (Hu & Ma, 2010). Additional studies have to confirm 
the presence of viruses in these animals. A recent study recovered and 
sequenced full genome HEV sequences closely related to gt4 from yak in 
China (Xu et al., 2014). A HEV-related virus was recovered in droppings from 
three dromedary camels in Dubai. These isolates were more than 20% 
divergent from other HEV types on the nucleotide level (Woo et al., 2014). 
They are most similar to viruses in the genus Orthohepivirus A, and assigned 
as gt7 (Smith et al., 2014). Sequencing partial HEV sequences revealed a HEV 
like virus in chimpanzee from a zoo in China (Zhou et al., 2014). Another 
novel HEV related virus was identified through partial sequencing using high 
throughput sequencing (HTS) on sewage samples from Nepal. This virus was 
shown to be highly divergent that it was suggested to be classified in a new 
genus (Ng et al., 2012). But several of these studies need to be confirmed by 
others and full genome is required for appropriate HEV classification.   
Other potential animal HEV reservoirs  
HEV antibodies have been detected in both cats and dogs (McElroy et al., 
2015; Liang et al., 2014), but still no HEV RNA has been isolated. Despite the 
suggested presence of anti-HEV, it has been difficult to detect and sequence 
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HEV-related virus RNA from these species. The serological results may be due 
to false positivity in the assays. This may also be due to low virus 
concentration in the sample or to high genome sequence divergence requiring 
an updated PCR assay, and which is discussed in studies I-II.  
1.5 Diagnosis and detection of HEV 
1.5.1 Detection of HEV RNA - a marker for active HEV infection   
The diagnosis of ongoing HEV infection can be obtained either by anti-HEV 
IgM detection or by direct detection of HEV. The latter can be done through 
molecular techniques that detect viral nucleic acid (HEV RNA) or through 
electron microscopy (EM) for finding of viral particles which provided the first 
evidence for the existence of HEV (Bradley et al., 1987). EM is unsuitable for 
clinical routine diagnostics because of the requirement of expensive 
equipment, low sensitivity, maintenance and skilled personnel. The preferred 
detection of HEV is therefore detection of viral RNA in feces and/or serum and 
if possible from liver samples. The viral RNA is present in the blood and/or 
feces for some weeks. The commonly used methods for detecting viral RNA is 
gel based- or quantitative real-time based- reverse transcription-polymerase 
chain reaction (RT-PCR) 
Conventional gel based RT-PCR 
For avoiding confusion with gel based RT-PCR, the term quantitative real-time 
RT-PCR is just abbreviated as qPCR throughout the thesis. The conventional 
gel based RT-PCR allows determination of genotype through sequencing, but 
there is increased risk for contamination due to several separate sample 
handling steps. The RT-PCR are used in this thesis for HEV typing by 
sequencing and amplification of larger HEV genomic fragments for sequencing 
near complete HEV genomes (Studies I-IV). 
Quantitative real-time RT-PCR (qPCR) 
The qPCR approach is now widely used, because it enables the detection and 
quantification of the viral nucleic acid, with high sensitivity and specificity for 
a reasonable cost, and is well suited for routine work. The qPCR requires no 
electrophoresis thereby avoiding contamination of the laboratory. However, the 
electrophoresis approach can sometimes not be avoided and is especially useful 
for confirming unclear positive qPCR results and for strain typing through 
sequencing. 
This thesis used two Taqman based qPCR HEV protocols, which are 
targeting the ORF1 terminal end or the ORF2/ORF3 overlapping region of gt1-
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4 (Gyarmati et al., 2007; Jothikumar et al., 2006). Both Taqman protocols have 
proven to be robust when compared with other qPCR protocols (Vasickova et 
al., 2012) and are therefore used for HEV screening followed with HEV typing 
by RT-PCR. The Taqman chemistry consist of a primer set that direct the 
sequence targeting and a dual labelled probe with a fluorophore and a quencher 
at each terminal primer end. The probe binding to target sequence, followed by 
activity of DNA polymerase (with 3’ exonuclease activity) will release the 
fluorophore and quencher through the elongation step of the PCR cycle 
(Kubista et al., 2006). The recording of light signals released by the 
fluorophore are interpreted with a machine and its software plots the 
fluorescence against the number of cycle on a logarithmic scale. The number of 
cycles where the fluorescence surpass a certain threshold level, which is set 
above background, and is designated the threshold cycle (Ct). This can be done 
automatically by the software or manually. In theory, the amount of amplicons 
doubles in every cycle leading to an exponential increase of fluorescence. 
However, in reality the efficiency of the amplification also depends on primers, 
templates and presence of potential inhibitors. This can be evaluated in parallel 
during the original experiment with serial dilution of DNA template as a 
positive control sample in separate tubes. A standard curve of the change in the 
Ct with each dilution can be plotted and its slope of linear regression is then 
used for determining the qPCR efficiency. 
1.5.2 Serological detection of anti-HEV markers for past/recent HEV infection  
Past infections leaves traces in form of antibodies, at least for some time. The 
antibody IgM is suggested as first indicator of recent or ongoing infection, and 
IgA can also be detected during acute HEV infection (Chau et al., 1993). 
However, not all strains/genotypes induce IgA antibodies and therefore more 
data are needed to clarify the diagnostic significance of these antibodies. The 
serological appearance of IgM and IgA is soon succeeded by IgG production 
which remain and may be detectable for up to 14 years (Emerson & Purcell, 
2003; Bryan et al., 1994; Khuroo et al., 1993; Dawson et al., 1992). The 
detection of anti-HEV antibodies using Enzyme-linked immune absorbent 
assay (ELISA) is a useful and very frequently used standard method for 
estimating the HEV prevalence. HEV specific antibodies remain detectable 
over more extended period of time compared to viral RNA. This enables 
diagnosis over a longer detection window. Despite the existence of gt1-4 and 
that gt3-4 infections in both humans and animals, only one serotype has been 
described until now. Thus, the same antigen of any gt1-4 can be used for 
detecting previous gt1-4 infections (Emerson & Purcell, 2003). All three HEV 
ORFs have been shown to have antigenic properties (Khudyakov Yu et al., 
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1994; Purdy et al., 1992). ORF2 has been shown to be more immunogenic, 
probably because this structural protein contain a variety of antigenic domains 
exposed to the immune system (Tsarev et al., 1993). This antigen is used in 
most serological assays.  
The detection of anti-HEV in humans or animals usually requires specific 
designed assays for each host. However, an approach that allows for the host-
independent detection is the double-antigen sandwich ELISA, which is useful 
for epidemiological investigations and this ELISA is used in study II and study 
IV. The antigen (ag) for e.g. HEV attached to solid area is used to capture 
specific antibodies from serum. The detection of the antibody is attained with 
the same antigen labelled with e.g. horseradish peroxidase (HRP) which is 
added and bound to the second variable domain of the bound antibody. When 
unbound labelled antigen has been removed, chromogen with hydrolysing 
agents are added and hydrolysed by the bound Ag-HRP of the antigen-
antibody-antigen sandwich complex, resulting in colour change (Figure 8).  
Figure 8. The general principle of the host independent the double-antigen sandwich ELISA. 
Abbreviation: ag: antigen, ab: antibody, HRP: Horse radish peroxidase. Pre-coated ag capture 
target ab from serum and detection of the ab is done with the same ag coupled with HRP which in 
present with chromogen and hydrolysing agents will result in colour change that can be detected.   
The amount of the colour intensity can be measured and is proportional to the 
amount of antibody captured in the sample and from the included positive 
control with standardized antigen. A useful feature of this assay is the lack of 
discrimination between classes of antibody, thus detecting total anti-HEV. An 
assay based on this was developed for detection of anti-HEV in humans and 
animal samples (Hu et al., 2008). It should be noted that there are currently no 
guidelines from WHO and no established standards when designing an assay 
for detecting anti-HEV antibodies. A wide selection of assays are 
commercially available as well as in house assays. The absence of guidelines 
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of HEV assays requires cautious interpretation and comparisons of 
seroprevalence data, because of different sensitivity and specificity for each 
assay used in the laboratories. As an example, a recent study demonstrated 
high variation from three commercial assays when analysing sera from 200 
apparently healthy healthcare workers and found 4.5%, 18% and 29.5% of the 
samples positive for anti-HEV IgG (Wenzel et al., 2013). Thus, continuously 
improved serological assays leading to a standardization are needed for 
providing more reliable and comparative serological data. For now, samples 
that are positive in anti-HEV assay may need supplemental test detecting HEV 
RNA to better estimate HEV prevalence.   
1.5.3 Cell culture and other animal model systems 
In general, the use of cell cultures for rapid detection of viruses for diagnostic 
purposes is limited as newer and faster methods of detection (quantitative real 
time PCR) has replaced cell cultures, however cell culture is very sensitive and 
is still the preferred methods for test of infectivity of a given sample, but also 
inoculation into susceptible laboratory animals can be used for such studies 
(Leland & Ginocchio, 2007). However, the absence of an efficient cell culture 
and small animal model for HEV have hampered the research on HEV. 
Additionally, the infectivity of HEV samples positive in qPCR e.g. food has 
not been easily demonstrated. Common approaches to the determination of the 
infectivity in swine or small animals have been used as infection models. 
However, this is not an optimal detection method for several reasons because 
of costs for labour and maintaining the animals as well as for ethical reasons. 
Cell culture models 
Replication of HEV in cell cultures is very challenging and difficult. This is 
reflected by the fact that only a small number research groups have access to 
cell culturing system that support growth of adapted strains of HEV. A cell line 
that is permissive to all strains is still not available. Some factors that are 
suspected for contributing to the troublesome HEV cell culturing are:  
a) the HEV positive samples normally have low viral loads. Higher virus titers 
increase the possibility of infecting cells and replication.  
b) additional unidentified receptors or other host factors required for optimal 
HEV replication may be missing in the 2D cell culture environment, which is 
available within the 3D-environment of the infected host.      
c) the HEV disintegrates when stored despite sample storage at low 
temperature, therefore if the cell culture is not performed soon after the 
collection of the sample, replication is less probable to occur (Huang et al., 
1999).  
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It is only in recent years that researchers have tried to culture different HEV 
strains in vitro on cell lines of human and animal origin (Okamoto, 2013). The 
first successful isolation of a human HEV strain was done on the human lung 
cancer cell line A549 (adenocarcinom human alveolar basal epithelial cells) 
(Huang et al., 1999). The first efficient HEV cell culturing system was the 
hepatocarcinoma cell line PLC/PRF/5 using a fecal samples containing gt3 
with 107 virus copies/ml from a Japanese patient with chronic renal failure 
(Tanaka et al., 2007). The same study also demonstrated the potential of the 
A549 cell line and observed that viral appearance and titer in the cell culture 
was largely dependent the initial original titer of the tested virus inoculum. 
Both PLC/PRF/5 and A549 cell lines have since then been used in several 
studies demonstrating repeated passages of replication of gt1, gt3-4 of both 
human and animal origin including strains from deer, wild boar and swine 
(Takahashi et al., 2012; Takahashi et al., 2010; Tanaka et al., 2009). 
Instead of culturing a monolayer of PLC/PRF/5, a 3D cell culturing system 
with this cell line supported by microspheres also demonstrated successful 
HEV replication (Berto et al., 2013b). This culturing system would possible 
give a more natural tissue-like dispersal of receptors on the cells, thus 
mimicking the in vivo environment. HEV replication was demonstrated on this 
3D culture system with samples from contaminated French pork liver sausages 
(Berto et al., 2013a). A recent study has further demonstrated HEV replication 
in the human liver cell line HepaRG and the porcine embryonic PICM-19, but 
the titers of the progeny virions were lower compared to PLC/PRF/5 and A549 
(Rogee et al., 2013). However, there are some issues that have to be taken into 
consideration when using the latter cell lines: The PLC/PRF/5 cell line has the 
hepatitis B virus genes incorporated in the cell genome which can 
unexpectedly affect the HEV infection; the A549 is not a hepatic derived cell 
line and therefore may not represent the replication in the liver (Rogee et al., 
2013). 
A special gt3 strain named Kernow-C3, isolated from a HIV patient with 
persistent HEV infection (Dalton et al., 2009) was shown to infect 10 cell lines 
from different species, as human, chicken, pig and deer (Shukla et al., 2011). 
This shows the potential cross-species infection capacity of HEV. In addition 
to PLC/PRF/5 and A549, the human cell line HepG2/C3A was shown to 
support the most efficient propagation of HEV compared to other cell lines. 
The detection of virions associated with lipids and ORF3 from cell culture 
supernatant and serum have been reported (Shukla et al., 2011; Takahashi et 
al., 2010) (Shukla et al., 2011), but their role and occurrence in natural 
infection have to be further studied.    
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The rabbit HEV, a distant gt3 related HEV, has been shown to replicate 
efficiently in both A549 and PRF/PLC/5 cell lines, suggesting a potential 
zoonotic risk of rabbit HEV (Jirintai et al., 2012). Another recent study showed 
interesting results when liver homogenates containing rat HEV, which was 
inoculated into human hepatocarcinoma cell lines, PLC/PRF/5, Huh7 and 
HepG2 cells, but no replication occurred in the A549 cell line. The rat HEV 
replicated in human PLC/PRF/5, HuH-7 and HepG2 cell lines, and the cells 
released progeny virion particles with lipid-associated membranes (Jirintai et 
al., 2014). This HEV infection across species barriers demonstrate that the 
zoonotic properties of the novel animal HEVs found in e.g. rat, moose (Study I, 
II and IV), ferret etc. cannot be ignored and should be further investigated. The 
continuous improvements of HEV cell culture systems is anticipated to 
contribute to the diagnosis of HEV infections and may offer ways of evaluating 
antiviral treatments.      
Animal model systems 
None-human primates (Chimpanzee and macaques) have been used as 
experimental models for all gt1-4. Other animal e.g. pigs, rabbit and rat could 
to certain extent be used for infection studies for gt-3-4 (Purcell & Emerson, 
2001). However, animal models have limitations in reproducing clinical 
aspects of human hepatitis, with minimal elevation in serum levels of liver 
enzymes and moderate present pathological liver lesions (Meng et al., 1997). 
Although HEV is believed to be fecal-oral transmitted in humans, most 
experimental infections with none-human primates have used intravenous route 
of HEV inoculation because a much higher dose is required for infection 
through the oral route (Arankalle et al., 1994). 
The swine model systems have been used to give a better understanding on 
the relationship of HEV genes, replication and cross-species/zoonotic abilities. 
The model supported replication of the first infectious clone of gt3 and helped 
in the identification of the authentic initiation start codon site for HEV ORF3 
(Huang et al., 2007; Huang et al., 2005). Moreover, studies of gt3 mutants in 
the HVR of ORF1 have shown that this variable region was non-essential for 
the infection and may play a role for the virus attenuation (Pudupakam et al., 
2009). The main drawback of this model is that it does not reproduce a hepatic 
disease with obvious clinical signs which makes it less suitable for 
pathogenicity studies.  
Other potential animals as HEV model system are chicken, rats and rabbits. 
As model for HEV infection in humans, avian HEV appears to be limited in 
host range, however they offer a unique hepatic disease model (HSS/BLS) that 
can be used to study some aspects of human hepatitis E disease. As with HEV 
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infection in swine, experimental infection in rabbits has a subclinical course 
(Ma et al., 2010). However, two recent studies may indicate new ways for 
using rabbit to better understand HEV pathogenesis in humans. The first study 
used specific pathogen free (SPF) rabbits, which led to the development of 
chronic HEV infection (>6 months) and associated liver fibrosis with a rabbit 
HEV strain and extrahepatic HEV replication e.g. in brain was also observed 
(Han et al., 2014). Interestingly, the chronic disease pathology was not seen 
when rabbits were infected with gt4. The pathogenesis of HEV in SPF rabbits 
is unclear, but may contribute to a better understanding of chronic HEV 
infection seen in e.g. immunosuppressed patients. The second study used rabbit 
as model system to increase our understanding of HEV pathogenesis during 
pregnancy. This study provided experimental result of adverse effects and poor 
outcome of HEV infection during pregnancy, including high maternal 
mortality, infertility and miscarriage. Vertical transmission associated with 
HEV replication in the placenta was also suggested (Xia et al., 2015).  
Thus, the expanding host range of HEV offers possibilities to identify 
potential new animal HEV strains that could lead to better development of 
animal model/s for HEV. Genetic identification and characterization of novel 
animal HEV strains are therefore desired together with an efficient in vitro cell 
culture. The possibility to propagate multiple strains of HEV will significantly 
contribute to improved cost-effective treatments and vaccine against HEV.  
1.6 Routes of transmission  
Several transmission pathways have been reported: mainly through 
contaminated water and food, but vertical transmission and person-to person 
transmission can also occur (Kamar et al., 2012a) Possible transmission routes 
are illustrated in Figure 9. 
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Figure 9. Possible and confirmed HEV transmission routes from reservoirs to humans. This is 
reproduced (Kamar et al., 2012a) with permission by Elsavier. 
1.6.1 Waterborne 
The water borne HEV epidemics are caused by gt1 and gt2 and most likely by 
fecal contamination of drinking water supplies (Kamar et al., 2012a). Several 
HEV epidemics are known to have occurred during in recent times and the risk 
for epidemics increases with natural disasters e.g. flooding, earth quakes and 
overcrowding in refugee camps (Table 1). The outbreaks are characterized by 
high morbidity and mortality among pregnant women and young children 
(Teshale et al., 2010b). 
1.6.2 Foodborne zoonosis  
The identification of the source of HEV infections caused by gt3-4 infections 
are not always straightforward because of the long incubation period from the 
moment of infection to the appearance of clinical symptoms. During this 
period, the food has usually been thrown away. However, several studies 
demonstrate that HEV may be present in the food chain (Berto et al., 2012; Di 
Bartolo et al., 2011; Leblanc et al., 2010). Many studies have confirmed that 
HEV may be prevalent in meat/livers bought from the grocery store in different 
countries e.g. Netherlands and Southern Germany with a HEV RNA 
prevalence of 4% with 0.8% in India and 2% in Japan  respectively (Wenzel et 
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al., 2011; Kulkarni & Arankalle, 2008; Bouwknegt et al., 2007; Yazaki et al., 
2003). In addition, there are studies that have documented zoonotic incidents 
associated with consumption of HEV infected food, where the retrieved HEV 
strain from the patients was identical or near identical with the strain recovered 
from the consumed food. Some examples of zoonotic transmission are reported 
from Europe and Japan. In southern France three out of five family members 
who consumed Figatelli, a liver sausage that is traditionally eaten raw, got 
hepatitis E (Colson et al., 2010). Virus isolated from the Figatelli has also been 
shown to be infectious in 3D culture systems (Berto et al., 2013a). A Japanese 
study collected a series of HEV infection among people who consumed 
uncooked dear meat and testing of both left over deer meat and patient, 
resulted in identical HEV sequences. Family members who consumed none or 
little of the meat remained uninfected (Tei et al., 2003). Another study from 
Japan reported two men, who independently from each other were admitted to 
hospital with severe hepatitis. The investigation showed later that the men were 
acquaintance and had consumed uncooked wild boar liver (Matsuda et al., 
2003). Consequently, consumers of pork products are exposed for potential 
HEV infections. 
In addition to consumption of infected pork products, the use of human or 
animal waste contaminated water for irrigation, may pose a risk for HEV 
transmission. The crop irrigation may also further distribute HEV 
contaminated water; into rivers, coastal waters and shellfish, which may cause 
disease in consumers (Crossan et al., 2012; Kamar et al., 2012a). However, 
data on possible association of HEV with vegetables and fruits are very 
limited. HEV RNA have been found on strawberries with high partial sequence 
similarity with another HEV strain detected on a swine farm in Quebec, but its 
infectious capacity has not been evaluated (Brassard et al., 2012). An outbreak 
involving passengers in a cruise ship returning from a journey in 2008 resulted 
in jaundice in four patients and out of 789 tested persons, 25% were 
seropositive, consisting of 4% IgM and 21% IgG seroconversion indicating 
recent/past HEV infections (Said et al., 2009). The genotype detected in the 
patients was gt3 similar to strains circulating in Europe suggesting a shared 
source of infection and consumption of seafood was considered a risk factor.  
1.6.3 Other routes 
HEV RNA and antibodies against HEV have been detected in healthy 
individuals and blood donors (Cleland et al., 2013; Baylis et al., 2012). HEV 
transmission by blood transfusion have been documented. (Matsubayashi et al., 
2008; Colson et al., 2007; Boxall et al., 2006). It is estimated that the majority 
(75%) of donated blood was given to immunosuppressed patients in the UK 
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(Bihl & Negro, 2009) and chronic HEV infection have been found in this 
patient group. Studies have shown an increase in the risk for extensive liver 
damage if chronic infection is left untreated, which could result in the need for 
liver transplantation (see chapter 1.3.1 regarding Chronic HEV infection). At 
the moment there is no obligatory screening of HEV markers in blood/organ 
donors. This may be changed in the future.  
Vertical transmission from mother to infant have been reported (Khuroo & 
Kamili, 2009). Several professions have also been associated with higher HEV 
infection risks, e.g. veterinarians, slaughter house staff, forestry workers etc., 
(Yugo & Meng, 2013; Carpentier et al., 2012; Dremsek et al., 2012). Markers 
of HEV have also been detected in pets like dogs and cats, and rabbit (Caruso 
et al., 2015; McElroy et al., 2015; Liang et al., 2014), suggesting pets as a 
potential source for human HEV infections. Observation of a human HEV 
strain that is genetic closely related to rabbit HEV strains and its ability to 
replicate in human cell lines and cause cross species infections in pigs 
reinforce the potential of HEV transmission from rabbits to humans 
(Cossaboom et al., 2012; Izopet et al., 2012; Jirintai et al., 2012). 
1.7 Adaptation and evolution of HEV 
1.7.1 General overview 
The genetic differences between HEV genotypes 1-2 and 3-4 may depend on 
different transmission pattern reflecting the host specificity. Several novel 
HEV types not related to gt1-7 have recently been discovered, including the 
moose HEV from studies I-II & IV. However, their cross-species abilities and 
their contribution to the general HEV evolution still remain unclear.  
Gt1 has previously been the dominating HEV type in China, however, there 
are signs that there is a decrease of Gt1 infections and an increase of gt4 
instead. The cause for this is unclear, but may reflect a changing lifestyle and 
improved water sanitation, which may favour HEV strains with zoonotic 
properties (Liu et al., 2012). Another perspective is that HEV may have taken 
advantage of the predator and prey relationship, which may be reflected by the 
hepatitis variants found in ferret, mink and fox, which have closest genetic 
relationship with rat HEV (Thiry et al., 2015). These hypothesis are some of 
the challenges for future HEV research to confirm.  
1.7.2 Genomic variability of genotypes 1-4 and quasispecies 
Although differences exist between the genotypes 1 to 4, the genomic 
variability still remains low, especially on the amino acid level. When 75 HEV 
isolates of gt1-4 with full/near complete genomes were compared, the inter-
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genotype difference was only 6.5-11.7% amino acid difference of ORF2. This 
high degree of conservation correlates to the reduced antigenic diversity and to 
the single serotype of HEV (Okamoto, 2007). Despite this limitation, a 
significant sequence diversity on the nucleotide level has been observed from 
different regions of the world, not to mention the high sequence diversity 
observed in recent novel animal HEVs. One of the factors for creating such 
diversity may be high error rate of the viral RdRp with absence of proofreading 
properties. The mutation frequency of a wide different RNA viruses ranges 
from 10-4 to 10-5 substitutions per base per round of copying (Domingo, 1996). 
The HEV mutation rate was estimated to 1.40–1.72 × 10−3 base substitution per 
site per year based on closely related isolates from Japan sampled 7.5 year 
apart (Takahashi et al., 2004b). The high error rate of viral RdRp contributes to 
an increased diversity of the replication virus strains within the infected host. 
In fact, this results in a mixture of closely related variants termed quasispecies 
for each virus strain (Grandadam et al., 2004). The quasispecies effect may 
contribute for the evasion from the immune system, and only some strains in 
the swarm of viruses, may have the ability to efficiently infect host cells. This 
could explain why high viral load is needed in cell culture and animal models, 
because only a fraction of the swarm is infectious. This may also contribute to 
the observed extrahepatic replication sites in swine and wild boar (Schlosser et 
al., 2014; Choi & Chae, 2003; Williams et al., 2001). For humans, this may 
possible manifest as neurological,  hematologic and autoimmune syndromes as 
has been observed during hepatitis E virus infection (Aggarwal, 2011).   
1.7.3 HEV recombinants emerging from uptake of additional nucleic acid 
fragments 
Several reports have shown that HEV recombination can occur by exchanging 
part of the genome or by additional fragments into the PPR, which is part of 
the HVR. The recombination could be the result of co-infection of different 
strains/genotypes (Smith et al., 2013b; Moal et al., 2012; Takahashi et al., 
2002). The uptake of fragments have been detected in gt3 isolated from chronic 
infected patients. The fragments could originate from the same infecting strain 
or from different stain due to co-infection of the host with several strains 
(Johne et al., 2014b; Lhomme et al., 2014a; Nguyen et al., 2011). Examples of 
acquirement of genetic material from the host have also been described. 
Segments of human genes were identified in the PPR of HEV RNA taken from 
a cell culture system (partial S17 ribosomal genes), (Shukla et al., 2012; 
Shukla et al., 2011) and from a chronic infected patient (partial S19 ribosomal 
gene), (Nguyen et al., 2011). The mechanism behind the insertion is still 
unclear. The fragment insertion into the PPR is suggested to have a host 
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adaptation effect, but it may also have a virulence property. Similar inserts 
have been observed in strains isolated from swine and patients indicating 
previously possible zoonotic events (Study III). The usefulness of the PPR as 
phylogenetic marker for tracing and comparing strains have been shown, which 
is demonstrated in study III. 
1.7.4 HEV origin hypothesis 
Did HEV appear first in animals or in humans? The answer to this question is 
still unknown. If the ancestors of gt1-4 is hypothesised to have been 
transmitted from humans to animals, then animals would act as viral reservoirs 
for maintenance of infection and reinfection HEV of mammals including 
humans. However, many of the animal species have an older evolutionary 
history than the human species, this could be interpreted that HEV have an 
animal origin instead. The roots of sequences from gt1-4 and rat HEV were 
estimated and suggested to have animal origin (Purdy & Khudyakov, 2010). 
Hosts of Orthohepervirus C have been detected in Carnivora, Rodentia and 
Soricomorpha, while members of Orthohepervirus A have recovered from 
Artiodatyla, Carnivora, Lagomorpha and primates. Such diversification of 
hosts indicate absence of co-evolution with its hosts, and suggest that HEV is 
an opportunistic pathogen (Smith et al., 2014). The future discovery of other 
HEV related viruses may not give the whole picture of the HEV origin, but at 
least progress the understanding of Hepeviridae evolution.   
1.8 HEV Prevention and control  
1.8.1 Virus survival and inactivation  
Information regarding the survival of HEV under various conditions in food 
and the environment as well as the effect of elimination procedures e.g. heating 
are important to better estimate the risk associated with the pathogen. 
However, in the case of HEV, there is currently no validated cell culture 
system. To study HEV inactivation, the majority of current studies rely on 
qPCR. Others have used in vivo testing to determine infectivity after the 
inactivation treatment, but these methods are not standardized and relative 
expensive (Cook & van der Poel, 2015). The few studies performed indicate 
that HEV remain infectious at temperatures used for cooking. The results 
showed that HEV could survive refrigeration (4ºC), freezing (-20ºC), (Cook & 
van der Poel, 2015), and heating to 71ºC for at least 5 minutes and that liver 
tissue may have a protective effect on the virus (Barnaud et al., 2012). 
There are a signifant gaps in our knowledge regarding the survival of HEV 
in food and in the environment as well as the effects of elimination procedures 
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used in the food chain. The necessary trials are dependent on the development 
of sensitive, cost effective and reproducible cell culture system, which will 
allow identification of HEV infectivity to be readily performed. This would 
further improve our understanding of HEV transmissions routes, develop 
control and prevention strategies of HEV contamination and transmission.  
 
Here are some points, partially adapted from Cock and Van der Poel (2015), 
that could contribute to the progress knowledge of survival and inactivation of 
HEV: 
- A robust cell culture for HEV is needed and else the recommended 
studies below cannot be easily done. 
- Additional studies are required to determine the heat effects on HEV, 
in free suspension and in food products, especially in swine meat. 
- The survival on surfaces should be determined, especially in in the 
food production facilities. The data generated should give a better 
knowledge and better understanding of the risk for cross-
contamination in the food chain. 
- The effects of disinfectants on HEV needs to be fully investigated. 
This is useful for selecting the most appropriate disinfectant for 
cleaning swine pens to reduce or eliminate risk for HEV transmission 
to swine and farmers. 
- Freeze-thawing may have a negative effect on HEV and this should be 
investigated as well. 
- Experimental inactivation studies comparing HEV with other 
microorganisms such as hepatitis A virus (HAV) and the highly 
resistant bacteriophages as PhiX174 should be performed to evaluate 
inactivation in absence of an efficient cell culture system. 
1.8.2 HEV therapeutics and vaccine 
The key strategy for preventing HEV infection (gt1-2) in developing countries 
is improving the sanitary infrastructure and vaccination with the newly HEV 
vaccine. However, vaccination would probably not be possible due to the cost. 
Therapeutics 
At the current stage, there is no established diagnostics and therapeutics for 
treatment of HEV. Antiviral treatment for patients with acute hepatitis E is not 
considered, only for patients developing fulminant hepatitis E (Izopet et al., 
2015). The identification of chronic HEV infections in immunosuppressed 
patients has led to different procedures to treat their infections, because if the 
infection is left untreated it may led to progressive liver damage (Fujiwara et 
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al., 2014). The first step is to reduce the immunosuppressive therapy, leading 
to clearance of one third of the patients (Kamar et al., 2011b). If the approach 
remains unsuccessful, then interferon and ribavirin treatment can be used 
(Izopet et al., 2015). Ribavirin is now the reference treatment for HEV 
infections (Izopet et al., 2015), but the mechanism on how it inhibits HEV 
replication is still unclear and requires investigation. More research of treating 
serious clinical outcome with HEV infection in pregnant women is also 
needed.  
Vaccine  
Vaccines can be efficient medical means to prevent viral infections. There are 
currently two vaccines based on the HEV gt1 and developed with recombinant 
technology, the rHEV (expressed in baculovirus) and the HEV239 vaccine 
expressed in E. coli that successfully passed phase II/III trials. The rHEV 
vaccine was developed GlaxoSmithKline and consists of a 56kDa recombinant 
protein from ORF2. The vaccine was 95.5% effective with three doses, when 
evaluating the safety and immunogenicity in a phase II trial on Nepalese Army 
volunteer in the Kathmandu Valley (Shrestha et al., 2007). Despite the success 
and potential of this vaccine, it is still not known if it will be marketed. The 
vaccine HEV239 is based on 26kDa protein translated in E. coli from ORF2 
which produces a 23nm VLP. It has gone through phase III trial and was 
conducted on 112,604 Chinese persons of which about 48,000 persons were 
administrated tree doses of the vaccine. The negative control group of similar 
size was administrated hepatitis B virus vaccine. The vaccine was 94-100% 
effective in preventing symptomatic cases of hepatitis E (Zhu et al., 2010). 
During the trials, pregnant women were also vaccinated and had no adverse 
effects of the vaccination (Wu et al., 2012). Unfortunately, vaccination would 
not be possible for the people who needs it, especially in the most poorest part 
of the world due to the economic reasons (Zhang et al., 2013).  
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2 Aims of the thesis  
 
The aims of this thesis were to provide understanding of the biology of HEV, 
its prevalence in different animal species, in the environment and the molecular 
epidemiology of hepatitis E virus (HEV). This will be useful to increase our 
understanding on how transmission across the species barrier occur, and if 
virulence can be predicted. The aim was also to increase our understanding of 
important risk factors for transmission of HEV from animals to humans in 
Sweden and elsewhere. 
 
The specific aims were: 
 
 to identify and characterize the genome of a new virus in moose and 
proving its relationship to the Hepeviridae family (Study I-II & IV).   
 
 to investigate the prevalence of HEV in moose in Sweden and its 
importance as HEV reservoir (Study II and IV).  
 
 to investigate HEV markers in the wild life of Sweden for the 
identification of additional HEV reservoirs. (Study IV) 
 
 to characterize and compare sequenced HEV strains from animals and 
humans regarding zoonotic transmissions by molecular and 
phylogenetic means. (Study I-IV) 
 
 to use a single HEV amplicon approach to amplify porcine HEV 
genomes and investigate their properties from a potential 
recombination, zoonotic and virulence perspective (Study III).  
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3 Material and methods 
This section summarizes the material and methods (M&M) used in the four 
studies of the thesis. Common basic sample storage and nucleic acid isolation   
approaches for all studies are summarized in section 3.1, followed by specific 
M&M for studies I-IV (3.2-3.5). 
3.1 General Material and methods approaches      
3.1.1 Sample types and storage 
Samples from swine were mostly in form of droppings and collected from 
several Swedish farms. In collaboration with certified hunters, samples from 
wild boar and different members of the deer family e.g. moose, were collected. 
From some animals, liver, bile, and kidney were also obtained. Multiple 
samples from the same individual were sometimes received. All samples were 
stored in -70ºC for long time storage and -20ºC respectively 4ºC degrees for 
short time storage. 
3.1.2 RNA isolation and cDNA synthesis 
Total RNA isolation from organs were performed according to the 
manufacturers’ instructions by homogenization in 2ml grinding tubes 
(Eppendorf) containing 2 mm zirconia beads (BioSpec Products) and 600µl 
buffer RLT from an RNeasy Mini kit (Qiagen). RNA in serum and feces was 
extracted with QIAamp Viral RNA mini kit (Qiagen, Germany) according to 
the manufacturers’ instructions. Alternatively, nucleic acid extraction was done 
in the EasyMag instrument (Biomerieux, Marcy l´Etoile, France) according to 
the manufacturers’ instructions. The concentration and quality of RNA was 
determined by NanoDrop (NanoDrop Technologies). The 20µl cDNA 
synthesis mix consisted of 1µl Oligo dT(20) (Invitrogen) or 1µl GeneRACER 
Oligo dT(24) (Invitrogen), used for priming cDNA synthesis with 3µl RNA, 1µl 
56 
(40 U) of RNaseOUT (Invitrogen) and 1µl (200 U) of Superscript III, RNase 
H− reverse transcriptase (Invitrogen). One microliter (end concentration 5 %) 
polymerase GC melt from an Advantage GC 2 polymerase mix kit (Clontech) 
was also added to facilitate amplification of high GC-content regions and 
reduce secondary structure formation in the HEV genome (Xia et al., 2008). 
The cDNA reaction was kept at 50°C for 60 min, followed by 15min 
incubation at 70°C. The reaction was finalized with 2U of E. coli RNase H 
(Invitrogen) for 20min at 37°C.  
3.2 Past and active HEV detection assays, gel-based PCRs and 
Sanger sequencing 
3.2.1 ELISA for detecting past HEV infections   
For detection of total HEV-specific antibodies representing past HEV 
infections (studies II and IV), sera were tested by double antigen sandwich 
ELISA (HEV Ab EIA, Axiom Diagnostics, Worms, Germany), performed 
according to the manufacturer’s instructions and the optical density (OD) was 
measured at 450nm. This assay was selected since it commonly used in 
European surveys, because it as good specificity and sensitivity and it is host 
animal independent for detection of total HEV antibodies 
3.2.2 Quantitative PCR for detecting active HEV infections   
Detection of HEV RNA representing active HEV infection was performed with 
a wide spectrum gt1-4 quantitative PCR (qPCR) assay (studies I, III and IV) 
with the following protocol: Three microliters of extracted and purified RNA 
were analysed using an Ag-Path-ID one-step RT-PCR kit (Applied 
Biosystems), with a total volume of 12.5µl containing 250nM JVHEV forward 
respective reverse primers and 100nM Cy5 based probe targeting the 
overlapping ORF2/3 region (Jothikumar et al., 2006) and 0.4×enzyme mix, or 
with primers targeting a sequence downstream of the ORF2 region with 500nM 
forward and 250nM reverse primers, 250nM, 260nM FAM based probe 
(Gyarmati et al., 2007) and 1×enzyme mix. Both methods have been shown to 
be more sensitive in comparison with other HEV detection methods 
(Vasickova et al., 2012) and using both methods increase the detection of 
clinical HEV positive samples. Although the qPCR assays was able to detect a 
more divergent moose HEV variant, probably with cross reactions, a modified 
one step TaqMan qPCR assay was constructed. It also targeted the ORF2/3 
overlapping region using the One step RT-PCR kit (Qiagen) (study II). The 
12.5μl PCR-mix contained 3μl of purified RNA, 600 nM each of primers HEV 
F8, HEV R8, and FAM-based probe P8, 1X PCR buffer, and 1X enzyme mix. 
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A 50μl PCR mix was used in study IV due to nucleic acid extraction in the 
EasyMag instrument. All qPCR samples were analyzed on a Rotor-Gene 3000 
instrument (Corbett Research, UK) with the following settings: 50°C for 30 
min, 94°C for 15 min, cycled 55 times between 94°C 15s and 60°C 60s. 
Fluorescence was monitored during the annealing step of each cycle. The 
diluted plasmid containing the full HEV genome of gt3 SWX07-E1 (Xia et al., 
2008) or with a plasmid containing a cloned 2.1kb moose HEV fragment (Lin 
et al., 2013) were used as a control and for the generation of standard curves. 
3.2.3 Gel-based PCR, terminal amplification and Sanger sequencing 
To acquire additional viral genomic sequence information, short fragment and 
long fragment PCR were performed: 
a) a commonly used PCR targeting the RdRp (Zhai et al., 2006) was set up 
(Study I, III and IV): a total PCR mix of 30 µl with 6µl of synthesized HEV 
positive cDNA template, 1.2U Platinum Taq polymerase (Invitrogen), 1×PCR 
RXN buffer, 1mM MgCl2, 0.2µM of each ESP and EAP primer, 5 % DMSO 
and 0.2mM dNTP. The cycling parameters were 95 °C 3 min, cycled 40 times 
94 °C 1min, 55 °C 1min, 72°C 1min and finishing with 72°C for 10min.  
b) the previous PCR protocol was modified for improved amplification of 
partial moose HEV RdRp (Study II): In the first PCR, the total reaction volume 
was 15μl containing 1X buffer, 0.2μM dNTP, 1mM MgCl2, 0.6U of platinum 
Taq polymerase, 1μl cDNA/PCR template and three pooled modified forward 
primers (Pool 1: ISP-4232A, ISP-4232B and ISP-4232E) and two pooled 
modified reverse primers (Pool 2: EAP-4576E and EAP-4576F) with a total 
concentration of 0.2μM for each pool. The semi-nested PCR contained the 
same reagents as the first PCR except that the reverse primer was replaced with 
three modified pooled primers (Pool 3: IAP-4561E, IAP-4561F and IAP-
4561M). In study IV, the semi-nested PCR was performed in 50μl reaction mix 
with 5µl cDNA, 31.9µl of RNase-free H2O (Sigma), 1xTaq buffer (Applied 
Biosystems), 2.25mM MgCl2 (Applied Biosystems), 0.2mM dNTP (Roche), 
0.3mM of each primer, and 1U of Taq polymerase (Roche). Primers ISP4232-
Pool0-H and EAP4576- Pool0-H were used for the first round PCR. Five µl of 
the first round product were used as template in the second amplification round 
with primers ISP4232-Pool 0-H and IAP4561-Pool 0-G. PCR reactions started 
with 94°C for 3min, followed by cycling for 40 times between 94°C for 40s, 
56°C for 30s and 72°C for 65s and finally 72°C for 10min. A double nested-
PCR with the same primers as in the second PCR was used for two purified 
PCR products with low amplicon concentration.  
c) with phusion PCR, longer amplicons could be amplified (studies I and 
III). The PCR mix contained 1µl cDNA as template with 0.15µl Phusion Hot 
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Start High-Fidelity DNA polymerase (Thermo Scientific, Finnzyme) with 
provided 1×GC buffer, 0.3µl 0.2mM dNTP, 0.5µM of forward primer, 0.5µM 
reverse primer and 0.45 µl DMSO (final 3 %) were also added in a total PCR 
volume of 15µl. The PCR program had the following profile: 98°C for 2min, 
then cycled 40 times 98°C 20s, Tm: 65 or 70°C 30s, 72°C 2-3min depending of 
amplicon size, and terminated with 72°C for 10min. Sometimes a Semi-
nested/nested PCR is needed for increasing the fragment concentration from 
the first PCR and specific downstream primers from both 5’ and 3’ were used 
instead. Depending of the aim of the PCR assay, different positive controls 
were used: Full genome of gt3 cloned within a vector (SWX07-E1), (Xia et al., 
2008). Clinical HEV positive from feces/liver samples e.g. gt3f strains Spanish 
SW8a24 from liver and SW46_8-Dalarna from swine feces were also used as 
positive HEV controls. Depending on the amplicon size, PCR products were 
verified in 0.8-2.0% agaros gel with GelRED (Biotium). Amplicons were 
purified with QIAquick PCR Purification Kit (Qiagen, Germany) or Wizard 
SV gel and PCR clean-up system (Promega) or PureLink Quick gel extraction 
kit (Invitrogen). The phusion PCR generated amplicons lacking the 3’terminal 
end overhangs required for TOPO XL cloning (Invitrogen). Therefore, poly(A) 
overhangs were synthesized before the cloning procedure in a 10µl reaction 
mix with final concentration of 0.2mM dATP, 1XPCR RXN buffer, 2.4mM 
MgCl2, 0.5U platinium Taq polymerase (Invitrogen) and 8.22µl of purified 
PCR product. The reaction was incubated in 72°C for 15 min and put on ice 
and cloning procedure was performed according to the manufacturer’s 
instructions. 
An approach called rapid amplification of cDNA ends (RACE) opens the 
possibilities to amplify the HEV terminal ends. Only the 3’UTR terminal end 
was amplified using a RACE kit (Invitrogen), and resulted in a 1.3kb 
overlapping PCR product according to PCR program profile 98°C 2min, 98°C 
10s, 65°C 30s, 72°C 2min and 72°C 10min. Sanger sequencing reactions were 
carried out with a Big Dye Terminator Cycle Sequencing Ready reaction kit 
version 3.1 (Applied Biosystems) with program profile 95°C 15s, 50°C 10s, 
60°C 4min cycling 25 times. The sequencing primers for moose HEV are 
found in Studies I-II and for porcine gt3 HEV in study III and for other HEV 
found in wild animals (Study IV).  
3.3 Sequence-, phylogenetic-, and statistical analysis 
3.3.1 General sequence analysis tools 
Different tools were used for sequencing analysis: Assembling and analysis of 
overlapping sequence regions into a consensus sequence was done with 
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Seqman within the DNAstar program package version 8 or 10. Detection of 
known and other possible open reading frame/s (ORF/s) were done in the 
NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and ORF finder 
(http://www.ncbi.nlm.nih.gov/gorf/gorf.html). Verified sequenced consensus 
HEV sequences (Study I-IV) were deposited to the the NCBI Genbank 
database (http://www.ncbi.nlm.nih.gov/genbank/) with assigned unique 
Genbank numbers. Some studies were used as supportive guidance for 
identifying ORF1, ORF2 and ORF3 domain/motif regions in the moose HEV 
genome (Ahmad et al., 2011; Xing et al., 2010; Koonin et al., 1992), (Study I-
III). HEV ORF1, ORF2 and ORF3 codon based multiple sequence alignment 
(MSA) of selected HEV regions/HEV genomes and phylogenetic analysis were 
performed with MEGA5 (Tamura et al., 2011) or CLC Genomic Workbench 7 
(CGW7). Nucleotide (nt) and amino acid (aa) sequence identity comparisons 
were done in CGW7. Region specific or more unspecific primers with 
nucleotide ambiguities were designed from MSA of several HEV 
genomes/genomic regions. Primers were ordered from Thermo Scientific 
Webshop (http://www.thermohybaid.de/). The MSAs often act as the backbone 
for other post-analysis and should be constructed with high consideration e.g. 
through codons.   
3.3.2 Phylogenetic relationship analysis of HEV 
The phylogenetic tree analysis is a useful method to better understand the 
phylogenetic relationship between newly sequenced genomic materials (Study 
I-IV). In terms of virus perspective, it is possible to apply the phylogenetic 
analysis e.g. molecular typing and tracing, detecting possible recombinations, 
geographical clustering, evolution and classification, especially on unclassified 
novel HEV variants to shed more light on the increasingly complex 
Hepeviridae family. The phylogenetic trees were codon based MSAs of 
various regions of different sizes e.g. on regions commonly used for typing in 
RdRp (Zhai et al., 2006) and ORF1 concatenated in frame with ORF2 
representing the full HEV genome. Maximum likelihood (ML) or neighbour 
joining (NJ) or unweight pair-group method using arithmetic averages 
(UPGMA) based approaches with 1,000 bootstrap were used for generating the 
trees in MEGA5 or CGW7 or PHYLIP package version 3.65.  
An alternative method for investigating genetic HEV relationship especially 
for new unclassified divergent HEVs was through calculating the amino acid 
(aa) p-distances (Smith et al., 2013a). The p-distance is the proportion of 
amino acid sites at which the two sequences to be compared are different. It is 
obtained by dividing the number of amino acid differences by the total number 
of sites compared. The p-distance separating the HEV genotypes was 
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suggested with a p-distance value of at least 0.06 (Smith et al., 2013a). A p-
distance/aa sequence divergent percentage matrix was generated with MEGA5 
using an in frame concatenated ORF-ORF2 MSA of different HEVs including 
the moose HEV (Study I).   
3.3.3 Possible recombination and identification of the moose HEV ORF2-3 
start codons 
Genetic material exchange through recombination is a common phenomenon 
within all organisms and viruses, and act as a factor for driving evolution. 
However, the detection of such events are not straight forward, but tools like 
the bootscan within the Simplot 3.5.1 tool 
(http://sray.med.som.jhmi.edu/SCRoftware/simplot/) can be used for detecting 
possible recombination events (Study III). The bootscan employed a 200bp 
window, 20 step with a ML based F84 as distance model with 1,000 replicates.  
The junction region (JR) with partial overlapping region covering the 
ORF1-end and the true ORF2 and ORF3 start codons were not easy to 
determine in the moose HEV. Therefore, a similar approach as in (Huang et al., 
2007) was performed to detect the possible “true ORF2 and ORF3 start 
codons”. A MSA of the gt1-4 JR containing putative cis-reactive element and 
putative start codons for ORF2-3 were analysed. The supportive secondary 
structure analysis with Mfold (http://mfold.rna.albany.edu/?q=mfold) for the 
JR of gt3 and the moose HEV were performed for supporting the MSA JR 
analysis (Study I). 
3.3.4 Statistical analysis 
To estimate apparent prevalence confidence intervals (Cis), one sample Z-test 
for proportions was used. A χ2-test for equality of two proportions was used in 
study II for analysis of significant difference (p<0.05) within age classes, sex 
and Swedish counties. The Fisher´s exact test was used in study IV. The 
statistical analysis were performed in R, version 3.0.2. 
3.4 High throughput sequencing (HTS) 
New and unknown viruses always pose a challenge to be detected, amplified 
and sequenced with traditional methods due to high sequence divergence in 
their genomes, or with low sample concentration. Therefore a high throughput 
sequencing (HTS) was performed for obtaining complete or near complete 
moose HEV genome with the Illumina MiSeq platform sequencing (Study II) 
as follows: 
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Synthesized dsDNA triplicates of the liver sample positive for moose HEV 
RNA (Study I) were diluted and prepared with Qubit dsDNA HS assay kit 
(Life technologies, USA) according to manufacturer’s protocol and the 
concentration was measured with Qubit 2.0 Fluorometer (Life technologies, 
USA). A 1ng sample (0.2ng/μl) was index library tagged with index 5 and 7 
(I5 and I7) primers and fragmented at the same time (tagmented) through a 5-
cycle PCR amplification using the Illumina Nextera XT kit, according to 
Illumina MiSec protocol. The samples were loaded on a chip and analyzed on a 
Bioanalyzer (Agilent Genomics, Germany) for DNA concentration, size, and 
size distribution. The DNA samples were diluted, pooled and a total input of 1 
ng DNA was loaded into a cartridge containing Technologies MiSeq v2 
Reagent 300 cycle kit, according to MiSec protocol. The assembled contigs 
from reads generated through de novo assembly with default settings in the 
CLC Genomics Workbench 6.0 were BLAST-searched for HEV and all 
putative HEV contigs were subsequently assembled into several larger 
consensus sequences. All remaining non-related HEV consensus sequences 
were removed. The 5kb algSWE2013 (KF951328.1) sequence (Study I) was 
compared with the MiSeq assembled HEV sequence, and the putative 5’-UTR 
terminal start position was identified through a MSA of Gt1 (AY230202), Gt3 
(EU360977) and Gt4 (HQ634346) genomes as templates. The Gt2 excluded, 
because the complete 5’-UTR sequence was absent. Identification of putative 
HEV domains was done according to (Koonin et al., 1992) and the “NCBI 
ORF Finder” was used for exploring new possible ORFs (Study II). 
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4 Result and discussion 
4.1 Detection, amplification, characterization and prevalence of 
hepatitis E virus found in Swedish moose 
4.1.1 Unclear HEV status in moose and collection of wild life samples  
Previous studies have shown that deer can be infected with HEV, cases with 
both gt3 and gt4 have been identified, and evidence for zoonotic transmission 
have also been documented (Choi et al., 2013; Tamada et al., 2004; Tei et al., 
2003). This is an emerging public health concern. The largest deer, the moose 
(Alces alces), which is regularly hunted for consumption in Scandinavia has 
not previously been investigated for HEV. This prompted us to screen markers 
of HEV in moose to see if this species also could act as a HEV reservoir for 
potential human transmissions. This could possible increase our understanding 
on why the HEV seroprevalence is unusual high (~9%) in the general 
population in Sweden (Olsen et al., 2006). This is not reflected in the reported 
clinical cases, because only up to 22 hepatitis E cases are reported yearly in 
Sweden, indicating that most HEV infections are asymptomatic, or not 
diagnosed. The proportion of zoonotic HEV transmission compared to the total 
numbers of HEV infections is still unknown. To get samples from wild animals 
is not a simple task, although the National Veterinary Institute (SVA) receive 
such samples on a regular basis, for screening for other pathogens. However 
the sample numbers were still not enough for serious studies. Therefore the 
Swedish hunters were asked to help with sending in samples of wild boar, 
moose and deer to both SVA and the Sahlgrenska Hospital.   
4.1.2  New HEV like virus found in a moose  
In Study I, two gt1-4 qPCR assays targeting the overlapping region of ORF2-3 
(Jothikumar et al., 2006) and ORF2 (Gyarmati et al., 2007), gave positive 
signal for HEV RNA in one out of six moose liver samples with Ct-values of 
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34 and 35 respectively. A kidney sample from the same individual was also 
found HEV positive with similar Ct-values. A partial HEV RdRp fragment 
frequently used for typing (Zhai et al., 2006) was obtained and sequenced, 
which showed surprisingly divergent HEV like sequence. With assistance of 
three overlapping PCR assays, a 5.1 kb partial moose HEV genome starting 
from the proline hinge region (PPR) of ORF1 covering both ORF2 and 3 to the 
3’ terminal end with the poly-A tail was acquired and sequenced. Additional 
upstream PCR fragment amplifications towards the 5’ end of the genome were 
unsuccessful, probably due to extensive sequence diversity. The sequence 
identity was 37-63% compared with existing HEVs and phylogenetic analysis 
showed that moose HEV formed its own separate branch between gt1-4 
including gt5-6. It separated from the other divergent animal HEVs like those 
found e.g. in rat, ferret, bat and fish. The ORF2 and ORF3 start codons were 
difficult to identify in the moose HEV genome. A secondary structure analysis 
with Mfold for the junction region (Huang et al., 2007) was therefore applied, 
which suggested that the ORF2 and ORF3 start codons were located in the 
stem forming the putative second loop structure of the junction region, when 
compared with gt3.  
These observation and the existence of three ORFs characteristic for HEV, 
clearly supported the classification within the Hepeviridae family. However, 
further subsequent classification was unclear due to absence of classification 
support in the current gt1-4 HEV grouping. At this time no new consensus 
HEV has been presented in the literature. Therefore, an alternative method for 
investigating genetic relationships with highly divergent HEVs was 
demonstrated with help of aa p-distances (Smith et al., 2013a). This approach 
was tested on the moose HEV and suggested it as a new species in the 
Hepevirus genus. Several nucleotide substitutions, some resulting in unique 
amino acid substitutions were detected in the 3’UTR, several motifs were also 
observed across the sequenced partial ORF1, ORF2 and ORF3. These 
mutations and the different secondary structures in the junction region may 
contribute to host specificity and possible virulence factors. An update of the 
current PCR assays was also required for optimal detection and amplification 
of moose HEV, due to its high divergence from other HEV types. 
4.1.3 HEV prevalence in Swedish moose  
To rule out that this novel HEV identified in the moose was not a single event, 
the prevalence of this virus was investigated in moose from an age group, 
gender and geographical (Swedish province) perspective (Study II). The HEV 
RNA prevalence was determined by an updated Taqman based qPCR (marker 
for active infection) with increased sensitivity from Ct=34-35, (Gyarmati et al., 
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2007; Jothikumar et al., 2006) to Ct=25 when tested on the same moose HEV 
positive sample from study I. This high titre of HEV RNA explains why the 
HEV positive moose sample in study I could be amplified with less optimal 
primers. No standard HEV serology method exists, especially not for moose 
HEV. Therefore, a host independent double sandwich ELISA assay to identify 
markers of past infection was used. The assays were tested on sera and 51 fecal 
samples from 231 Swedish moose shared with another study for investigating 
Anaplasma phagocytophilum infection in moose (Malmsten et al., 2013). Like 
with wild boar that is commonly infected with HEV (Widén et al., 2010; de 
Deus et al., 2008b), moose was also found frequently infected as indicated with 
markers of active and past infection found in 67 (29%) animals. While 34 
(15%) were positive for HEV RNA, 43 (19%) were seropositive for anti-HEV 
antibodies, and 10 (4%) had both markers. The detection of HEV RNA in 
serum and/or feces or both in some moose most likely mirrors stages in the 
infection cycle. As with swine (Yugo & Meng, 2013), the fecal-oral route is 
suggested as the main HEV transmission route between moose, because HEV 
RNA was detected in feces of some animals, but other routes cannot be 
overlocked. 
The only significant difference in prevalence of infection was found in the 
HEV seroprevalence of the 2-4.5 year old age group compared to 0-1.5 year 
age group (p<0.05), indicating that HEV immunity increase with age. A trend 
was detected with the largest proportion of active HEV infection presenting in 
the 0-1.5 year old age group, which was also found with the tick-borne 
pathogen Anaplasma (Malmsten et al., 2013). The decline of passive immunity 
may explain why this age group is infected with the pathogens for the first 
time. Anaplasma is known to have immunosuppressive properties and 
frequently infect moose (Malmsten et al., 2013; Rikihisa, 2011), which may 
make the moose more prone for HEV infections and prolong the infection time 
period. This has been observed in swine experimentally co-infected with 
porcine reproductive and respiratory syndrome virus and in immunosuppressed 
humans (Salines et al., 2015; Aggarwal, 2011). A hypothesis is that ticks may 
act as a vector for potential HEV transmissions, but more studies are required 
for confirming that statement. 
Near complete moose HEV genome sequencing 
A near complete moose HEV genome was high throughput sequenced (HTS). 
The moose HEV genome appears to be a middle sized HEV genome of around 
7kb with 35-60% nucleotide sequence identity to other HEVs. Three main 
ORFs characteristic of HEV were also identified, but also additional putative 
ORFs were detected, distinguished from the potential new ORFs found in 5’-
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terminal end in rat and ferret (Raj et al., 2012; Johne et al., 2010a). However, 
the existence of these potentially new HEV ORF’s have to be confirmed in 
future work. 
Phylogenetic and relationship classification 
The partial RdRp sequence of the thirteen moose HEV sequences and in frame 
ORF1 concatenated with ORF2 representing complete moose HEV genome, 
demonstrated a separate monophyletic clade formation with a common 
ancestor to gt1-6. Closer inspection of the 13 sequenced partial HEV RdRp 
sequences showed a high similarity to each other resulting in lack of: 
a) apparent distinct geographical clustering, contrary to what was observed 
with HEV strains isolated from rat and Swedish swine/wild boars in previous 
studies (Johne et al., 2012; Widén et al., 2010; Norder et al., 2009). 
b) extensive polyphyletic divergent strains, as previously observed for other 
animal HEVs like rat HEV and avian HEV (Mulyanto et al., 2014; Bányai et 
al., 2012; Bilic et al., 2009). These observations may be due to that the virus 
has recently been introduced into the moose population. The unsuccessful 
sequencing of all 34 qPCR HEV positive samples could be due to a 
degradation of the HEV genome during RNA extraction procedure and several 
freeze-thawing cycles of the RNA; or low virus concentration in the samples 
(the average Ct-value of 34.5); or lower sensitivity of the conventional PCR 
assay compared to qPCR. Unsuccessful sequencing of HEV RNA positive 
samples was described in other studies as well. It may reflect a higher sequence 
diversity than expected (Kukielka et al., 2015) or a combination of all above 
mentioned factors.  
 A gt1-4 qPCR assay was also applied for screening the moose samples for 
the genotypes with known zoonotic properties, but with negative results. Thus, 
the question if moose is susceptible to gt3-4 infection or if other deer species 
are infected with moose HEV still remains unclear. The phylogenetic 
relationship of moose HEV to the other HEV types showed the highest 
sequence identity (~60%) with gt1-6, suggesting moose HEV being a new 
member of the recently proposed species Orthohepevirus A (Smith et al., 
2014). This classification can be confirmed with identification of new animal 
HEV like viruses. But, the close genetic similarity to strains with zoonotic 
properties makes the moose HEV significant and its potential zoonotic 
properties can therefore not be ignored, because moose is regularly hunted and 
consumed in whole Scandinavia and other parts of Europe. 
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4.2 Genomic characterization of potential recombination, 
zoonotic and virulence elements in porcine HEV genomes  
4.2.1 Genomic characterization of the frequently found subtype 3f 
For the moment only one complete genome of a Swedish swine HEV of 
subtype gt3f is available, SWX07-E01 (Xia et al., 2008). Previous studies have 
shown that this subtype is frequently found in clinical human cases and in 
swine/wild boar in several European countries e.g. Sweden, France and Spain. 
The reason is unclear why specifically 3f is commonly spread, but may be 
related to improved adaptability and virulence properties. Typing of HEV is 
usually done by partial sequencing. Although sequencing of the complete HEV 
genome would give a broader and more correct phylogenetic relationship with 
other HEVs, it is not always feasible because it requires time consuming 
overlapping PCRs. In study III, a single amplicon PCR approach was applied 
using cDNA synthesised from RNA extracted from either sera or feces from 
swine and wild boar. This resulted in amplification of near complete porcine 
HEV genomes of ~7kb. All three ORFs characteristic for HEV were identified 
in all six near complete porcine hepatitis E virus genomes that were of subtype 
3f. One of the strains, 8a24, was from a Spanish slaughterhouse, the others 
were of Swedish origin, two from wild boar and three from domestic swine in 
different Swedish pig farms. All Swedish strains were similar to each other and 
to the existing Swedish strain SWX07-E1 with 89-92% sequence identity 
throughout their genomes, and with lower genomic identity (86-87%) to the 
Spanish HEV strain 8a24. This Spanish HEV strain also had a larger genome 
(7.3 vs 7.2 kb) than the Swedish strains.  
The increase of size of the Spanish HEV genome was identified in the PPR, 
which was shown to have a duplication, upstream PPR (uPPR) and 
downstream PPR (dPPR). Due to the nature of a duplication, it is difficult 
determine which of the uPPR or dPPR was the original fragment. The sequence 
similarity and the phylogenetic clade formation implied that a past co-infection 
of different HEV strains could have occurred, possible within a Spanish swine. 
Thus, the high similarity of the Spanish swine 8a24 strain with a French human 
HEV strains indicated that possible past zoonotic transmissions cannot be 
overlooked. The PPR region has a high genetic variability especially in the 
zoonotic gt3 and is suggested to have a role in HEV adaption to a new 
host/organ tropism, in modulating the host immune response and in virulence 
of the strain, possibly by opening new protein-protein interaction sites 
(Lhomme et al., 2014a; Lhomme et al., 2014b; Purdy et al., 2012). 
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4.2.2 Phylogenetic relationship and potential HEV recombinations  
The separate Swedish branch of HEV strains belonging to subgroup 3.II, 
within the subtype 3f shown by analysis of partial HEV sequences (Widén et 
al., 2010), was verified the phylogenetic relationship of the near complete 
HEV genomes. The 8a24 strain was found forming a cluster with 
French/Spanish 3f strains from both human and swine. The geographical 
clustering based on partial genomic sequences isolated from swine, wild boars 
and to some part from patients (Widén et al., 2010; Norder et al., 2009) was 
not found when complete genomes were phylogenetically analyzed. This 
indicates that sequence divergence along the near complete genomes may have 
been caused by other factors than just introduction of mutations by the viral 
RdRp. Recombination was therefore analyzed by the bootstrap program of the 
porcine HEV strains, which suggested a potential exchange of genetic 
information. This may have occurred between Swedish swine and wild boar 
HEV strains, between swine from different herds in the same province, and 
between the Spanish pig strain 8a24 and French human strains. Possible 
inter/intra genotype recombinations have been described between swine and 
human HEV strains, especially for gt3-4 (Chen et al., 2012; Wang et al., 2010; 
Fan, 2009; van Cuyck et al., 2005). Recombination events may be the result of 
either co-infection or superinfection of the same host with multiple strains as 
has been shown an immunocompetent hepatitis E virus infected individual and 
in a patient with acute hepatitis E (Smith et al., 2013b; Takahashi et al., 2002).  
Today´s global swine trading may be one of several factors facilitating the 
geographical spread of HEV strains and their interaction with each other, 
which may lead to a dilution of the geographic clustering pattern in the 
complete HEV genomes observed here both from a local and international 
perspective. Suspected recombination events involving different host species 
need to be more studied, as they may have implications for the evolution of 
HEV, especially it’s potential to emerge and adapt to new host, which may 
change/reflect its virulence. 
4.2.3 Zoonotic and virulence elements 
Specific markers of virulence in HEV is still not known. The immunological 
reactions are important for the outcome in acute/fulminant cases and high 
mortality rate in pregnant women (see chapter 1.3.1). Induction of more 
aggressive immune response may be related to some certain HEV strains with 
particular mutations across the genome (Bu et al., 2013; Mishra et al., 2013; Fu 
et al., 2011; Inoue et al., 2009; Takahashi et al., 2009). The subtype 3f is 
frequently found in swine herds and humans in Europe (Widén et al., 2010; 
Legrand-Abravanel et al., 2009; Norder et al., 2009) for unclear reason. One 
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possible explanation could be increased virulence properties. The presence of 
potential zoonotic and virulence elements throughout the amplified gt3 porcine 
HEV genomes were therefore investigated in the sequenced strains. Although 
all porcine 3f strains partially share mutations associated with virulence 
elements from patients with acute and fulminant hepatitis E (study II), they are 
still suggested as low virulence strains, with the SWX07-E1 strain being most 
virulent among the studied strains. If segment inserts in the PPR are marker for 
virulence, the order of virulence of the studies strains would probably change 
and put the SW8a24-Spain as the highest virulent strain. Even if most Swedish 
porcine HEV genotype 3f strains appear to have a low virulence profile, their 
significance for future public health should not be disregarded. The zoonotic 
ability of these strains has shown a remarkable dynamic adaptation for cross-
species transmission and persistence in immune suppressed patients, perhaps 
due to fragment insertion/s in PPR, as exemplified with the SW8a24-Spain 
strain. The PPR and its possible insert may therefore be useful as a 
phylogenetic tracing-, virulent marker and perhaps also as a medical target for 
developing drugs binding to this region.  
4.3 Wildlife as potential HEV reservoir 
The HEV seroprevalence in several developed countries is high and most 
sources of infection need to be identified. Wildlife has long been suspected to 
be a source for viral infections. Studies have shown that several species of 
deer, including moose (studies I-II, IV) and wild boar can be infected with 
HEV (Widén et al., 2010). In fact, zoonotic cases have been reported on 
individuals having consumed wild game meat of both deer and wild boar (Choi 
et al., 2013; Tamada et al., 2004; Tei et al., 2003). Swedes often go into the 
forest to pick berries and mushrooms, and it is also customary to consume wild 
game. With these fact in hand, the study IV was therefore performed to 
investigate if the Swedish wild life may constitute one route of HEV 
transmission to humans.   
4.3.1 Prevalence of HEV markers in wild life 
HEV markers were found in about 53 (22%) of the 245 animals from a total of 
466 samples consisting of serum and fecal samples. The HEV seroprevalence 
among the animals was estimated between 5-14%. No anti-HEV was detected 
from the fallow deer samples, most likely due to low numbers of samples. 
Although indication of regional difference and spread of specific HEV strains 
were observed previously (Widén et al., 2010), it could not be detected in 
study IV. Regional differences in HEV prevalence, between 5% and 88%, 
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related to animal density, have been shown for wild boar in Poland, Germany 
and Italy (Larska et al., 2015; Martinelli et al., 2015; Montagnaro et al., 2015; 
Adlhoch et al., 2009; Martelli et al., 2008). The uneven sampling from both 
different species and provinces may have contributed to the absence of regional 
HEV differences in this study IV.  
Wild boar  
The overall HEV prevalence (marker of both active and past HEV infection) is 
estimated to 19% (study IV). No significant difference in age between the 
younger and older animals with anti-HEV, although a trend was towards higher 
anti-HEV prevalence in older wild boars than in younger animals 5% vs 13%, 
compared to the total anti-HEV prevalence of 8%. There was no significant 
difference between HEV RNA detection and age of the animals. However 
significant HEV RNA difference was found, since moose showed more often 
active HEV infection than wild boar. It is known that wild boar are frequently 
infected by other pathogens and some have immunosuppressing properties as 
experimental tested or observed in swine (Salines et al., 2015; Schlosser et al., 
2014), which may result in partial HEV immunity. This could lead to multiple 
HEV infections during their lifetime, which is reflected in the absent of age 
differences of both active and past HEV infections. Although the HEV RNA 
prevalence apparently remain constant of 8-9% during almost 10 years when 
compared to wild boar samples collect during 2005-2007 (Widén et al., 2010) 
to 2015 (study IV). However, study IV also investigated HEV RNA prevalence 
in wild boar fecal and serum samples, which adjusted the total HEV RNA 
prevalence to 13%. This clearly shows the underestimation of active HEV 
infection and the need for both fecal and serum samples, which has been 
suggested in study II. Nevertheless, the HEV prevalence and similar frequency 
of animals with active and past HEV markers in serum and feces have also 
been observed in other European countries as well (Martinelli et al., 2015; 
Rutjes et al., 2010; de Deus et al., 2008b). It can therefore be concluded that 
this animal species is a possible natural reservoir for HEV in the environment 
in many countries.     
Different deer species (moose, red deer, fallow deer and roe deer) 
Additional near 30 moose of a total of 67 animals resulted in with HEV- 
seroprevalence of 14%, RNA prevalence of 27%, and total HEV prevalence of 
37%. This confirmed our previous finding that HEV is as prevalent in moose 
as in wild boar (study II). There was no significant difference of HEV RNA 
and anti-HEV between ages of the animal, although a trend was detected 
towards increased anti-HEV with age. In study II this trend resulted in 
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significant difference, which may be due to larger sample size. HEV was 
excreted in feces slightly more often by younger than older animals, but was 
found in blood at equal frequency regardless of age of the animal. The 
prevalence of HEV markers was equal between moose, younger and older than 
one year. As with study II, the zoonotic gt3 could not be found in moose, and 
larger sample size may be required for its detection. 
Although having only 39 samples from three other deer species excluding 
moose, HEV seroprevalence could be detected in 3 (7%) of the animals. 
However, no HEV seroprevalence was detected for the five fallow deer, most 
likely due to a small number of samples. A weak qPCR reactivity was detected 
from two red deer and one fallow deer. Difficulties with HEV detection in deer 
samples have been shown to be common in other studies in Europe (Larska et 
al., 2015; Serracca et al., 2015). On some occasions, gt3 strains have been 
identified in some of the qPCR HEV positive samples from red deer originated 
from Spain and Italy, and this genotype also infects swine and wild boar in 
these countries (Di Bartolo et al., 2015; Kukielka et al., 2015). Usually, most of 
the HEV qPCR positive samples cannot be sequenced, which could be due to 
low virus concentration or to a divergent HEV like strain, which probably 
require another assay for its detection and characterization. The moose HEV 
from studies I and II, and wild boar gt5-6 (Sato et al., 2011; Takahashi et al., 
2011) are example divergent animal HEVs.  
Nonetheless, the detection of HEV markers in the deer family indicated that 
these animals may be potential sources for HEV transmission, also in Sweden.  
4.3.2 Wild life HEV transmission routes to humans  
Both wild boar and deer share habitats and have been shown to transmit gt3 
and gt4 through consumption of undercooked or raw food products taken from 
infected animals both in Japan and Korea, (Tamada et al., 2004; Tei et al., 
2003). If European roe deer and/or wild boars also are infected with genotype 4 
strains, it may explain the few sporadic genotype 4 human cases in Europeans 
without any travel history before their hepatitis E infection (Colson et al., 
2015; Bouamra et al., 2014; Midgley et al., 2014; Choi et al., 2013).  
Autochthonous Swedish human HEV cases     
Out of 14 Swedish autochthonous HEV cases investigated in study IV, at least 
three persons were infected with HEV strains similar or identical to strains 
infecting wild boar. Since some of the infected persons are vegetarians or have 
not consumed meat before falling ill in hepatitis E, an alternative route than 
consumption of infected wild game or swine meat must exist. One pathway 
may be through irrigation of vegetables or berries with contaminated water as 
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has been shown for strawberries (Maunula et al., 2013). Since most of the 
surveyed infected animals excreted HEV in feces (study IV) and a previous 
study reported that urine as well as feces may contain HEV RNA (Bouwknegt 
et al., 2009). An alternative transmission may occur through contaminated 
berries and mushrooms.  
The overall results suggest that certain Swedish wild animals are frequently 
infected with HEV and may be a significant source for human HEV 
transmissions, either by direct contact or through consumption of game meat, 
to which attention should be given by the future public health in Sweden. 
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5 Concluding remarks 
 High prevalence of HEV markers (~22%) in Swedish wild life suggest 
wild boar and deer family as viral reservoirs and may result in human 
HEV transmission. 
 
 An absence of HEV prevalence differences between young and old 
animals in wild life indicate that the animals may have partial HEV 
immunity. Possible caused by co-infection with other pathogens, and 
thereby be susceptible to re-infection with HEV.  
 
 Human transmission routes of HEV may be through undercooked or 
raw meat/products from wild life and domestic swine. An alternative 
HEV pathway may be through consumption of berries and 
mushrooms, contaminated with urine or droppings from HEV infected 
wild animals. 
 
 Surveying for markers of ongoing or past HEV infection (HEV 
RNA/anti-HEV antibody serology) in the human and animal 
population gives important information on circulating strains. Such 
analysis may indicate on animal-virus relationship which may relate to 
zoonotic transmissions and may be used for reducing/prevention of 
virus transmission. However, extensive collaboration over the 
different professional fields is required, resulting in one health 
perspective. 
 
 Surveying markers of HEV in both human and animals may lead to 
the discovery of new divergent HEV like viruses, like the discovery of 
moose HEV. Screening for HEV in fecal and/or serum samples is 
feasible, and are easier accessible compared to obtain liver and bile 
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samples. If several sample types from the same individual could be 
obtained, the estimation of the HEV prevalence will be more accurate.   
 
 The moose is just as commonly infected with HEV as Swedish wild 
boars. The moose HEV has closest similarity to members of the newly 
species of Orthohepevirus A, encompassing HEV gt1-7. This genetic 
relationship to the zoonotic gt3-4 indicates that moose HEV cannot be 
ignored as having zoonotic potential.  
 
 High throughput sequencing opens the possibility to sequence samples 
containing highly divergent HEV variants, which would be very useful 
in combination with traditional approaches to identify and characterize 
new viruses.  
 
 The cross-species properties of moose HEV to infect humans and 
other deer species are still unclear. It is also not known if moose can 
become infected with HEV gt3. 
 
 Current results based on partial HEV moose genomes suggest that the 
moose HEV strains are all genetic closely related, without 
geographical clustering or other regional differences, indicating either 
that the virus has recently been introduced into moose, or that there are 
other constraints against diversification of this virus. There may also 
be limitations of the used assay for determining more divergent 
strains.    
 
 Phylogenetic analysis based on partial genome sequence is still useful 
for epidemiological studies for comparing circulating strains in 
animals and humans and for tracing source of infection.  
 
 The single HEV amplicon PCR approach opens the possibilities to 
amplify and clone near complete HEV genome for characterization of 
the genome from a phylogenetic perspective as well as for studying 
recombination events and possible evolution of quasispecies.   
 
 Complete genome sequencing enabled detection of possible 
recombination events between Swedish swine/swine herds/wild boars, 
and that there may have been zoonotic transmission of HEV strains 
between Spain and France.   
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 Investigation of possible virulence markers in porcine HEV of this 
study suggested low virulence of the subtype 3f strains. But the very 
high adaptability of the gt3 strains can quickly lead to a more virulent 
strain in a short time, which was observed in immunocompromised 
patients. 
. 
 The nucleic acid insertion in the HEV ORF1 PPR may have given the 
virus adaptation properties to the host and potential virulence. This 
PPR with and without insertion has a potential to be used for tracing 
the spread of a strain by phylogenetic analysis and for identification of 
virulence marker.                
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6 Future perspectives  
 Highly robust, cost-efficient and simple cell culture accepting all HEV 
strains are desired to better understand the general lifecycle and cross-
species properties of HEV. This is also needed for developing 
improved therapeutic HEV agents and vaccine. 
 
 Screening for moose HEV with assay targeting this HEV variant 
should be performed with other deer species and on human samples 
for investigating the possible spread of moose HEV infections.  
 
 More complete moose HEV genomes are needed to better understand 
the genomic variations of this HEV variant.  
 
 More HEV screening of wild life samples is required to confirm if gt3 
is present in Swedish deer or other wild life species, besides wild boar 
and domestic swine.   
 
 Host range adaption of HEV from a predator-prey HEV relationship 
still needs to be investigated. 
 
 The continuous identification and characterization of new HEV 
variants are needed to better understand the origin and evolution of 
HEV. This would also give more knowledge about how HEV would 
be classified in the future.   
 
 Inactivation of HEV in food and food products is still poorly 
understood, and further work and surveillance are needed to prevent 
the spread of HEV through the food chain.   
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